WO2009018549A1 - Therapeutic compounds - Google Patents

Abstract

The invention provides compounds of formula (I) wherein A, B, R1, F, G, n, n' and the dotted line have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.

Description

THERAPEUTIC COMPOUNDS

Priority of Invention

This application claims priority from U.S. Provisional Application Number 60/953660, filed 2 August 2007, which application is incorporated by reference. Background of the Invention

A diverse array of compounds, including anthraquinones, acridines, cationic porphyrins, perylenes, thidium derivatives, fluorenones, pentacyclic acridinium salts, fluoroquinophenoxazines, and other specific miscellaneous polycyclic compounds, have been reported to stabilize G-quadruplex DNA. Most of these compounds have little or no selectivity for G-quadruplex vs. duplex DNA.

Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 (Shin- ya et al, J. Am. Chem. Soc, 2001, 123, 1262-1263). At the time of its discovery, telomestatin was viewed as the most potent inhibitor of telomerase. In vitro, telomestatin stabilizes G- quadruplex vs. duplex DNA in a 70:1 ratio (Kim et a!., Cancer Res., 2003, 63, 3247-3256). It has been suggested that telomestatin also inhibits telomerase function in vivo, since cells treated with the natural product exhibit a cellular senescence phenotype. Like telomere dysfunction, telomestatin activates the ATM signaling pathway. While the precise mechanism by which telomestatin interacts with a G-quadruplex has not been definitively elucidated, telomestatin does suppress the plating efficiency of K62 leukemia cells but has a much lesser effect on burst- forming units - erythrocyte (BFU-E) and colony-forming units - granulocyte/macrophage (CFU- GM) from natural bone marrow CD34-positive cells (Tauchi et al, Oncogene, 2003, 22, 5338- 5347).

Telomestatin

The anticancer potential of telomestatin resides in its telomerase inhibitory activity (IC50 5 nM) and in its ability to enhance apoptosis. Telomestatin has been evaluated for cytotoxicity in the human neuroblastoma cell lines SK-N-AS, LAN5, WAC2, and LANl with IC₅₀ values of 0.8, 2.5, 3.2, and 4.0 μM respectively (Binz et al, Eur. J. Cancer, 2005, 41, 2873-2881) and in the human pancreatic carcinoma MiaPaCa with an IC_5O value of 0.5 μM (Liu et al, Nucleosides, Nucleotides, and Nucleic Acids, 2005, 24, 1801-1815).

Another macrocyclic polyoxazole, YM-216391 isolated from Streptomyces nobilis is active against the human breast cancer cell lines HBC-4, BSY-I, HBC-5, MCF-7, and MDA- MB-231 with GI₅₀ values ranging from 15-33 nM (Sohda, K-y., et al., J. Antibiotics, 2005, 58, 27-31 and Sohda, K-y., et al., Hiramoto, M., Suzumura, K-L, Takebayashi, Y., Suzuki, K-L, Tanaka, A. J Antibiotics, 2005, 58, 32-36).

The mechanism of action of YM-216391 has not yet been elucidated.

Currently, there is a need for novel therapeutic agents and therapeutic methods that are useful for treating diseases such as cancer. Such agents may have improved binding affinity for G-quadruplex DNA and/or they may have advantageous drug-like properties. Summary of the Invention

The present invention provides compounds that possess anti-cancer properties. Accordingly there is provided a compound of the invention which is compound of formula (I):

(I) wherein: one of A and B is -CH(R^b)CH(R^c)C(R^d)(R^e)-; and the other of A and B is:

; -CH(R^a)NHC(=O)- or -CH(R^b')CH(R^c')C(R^d')(R^e')-; one of F and G is X and the other is C(R^); each X is independently NH, S, or O; the dotted line in the ring containing F and G signifies that two double bonds are present in the ring, the positions of which depend upon the values selected for F and G; n and n' each independently represents 1, 2, 3, 4 and 5, provided that the sum of n and n' is 6;

R^a represents hydrogen, (Ci-C₆)alkyl, (C₂-C₆)alkenyl, (CrC₆)alkoxy or (C₁- C₆)alkanoyloxy, wherein each (CrC₆)alkyl, (C₂-C₆)alkenyl, (C₁-C_ό)alkoxy and (C₁- C₆)alkanoyloxy is optionally substituted with OH, (C₁-C₆)alkoxy, (Ci-C₆)alkylthio, aryl, heteroaryl, NRⁱRS, or -C(=O)NRfR§; and wherein each aryl and heteroaryl is optionally substituted with one or two substituents selected independently from halo, hydroxy, (Cr

C₆)alkyl, NR^fRg, and NRfRS(C ,-C₆)alkyl-

R^b and R^c each represents hydrogen, or R^b and R^c together represent a bond or -O- ; R^d and R^e together represent (=0) or R^d represents hydrogen and R^e represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=O)OR^S or CH₂C(=O)NR^mRⁿ, wherein each (Ci-C₆)alkanoyloxy is optionally substituted with one or more NR^lR^u; Rb' and R^c' each represents hydrogen, or R^' and R^c'together represent a bond or -O-;

R" and R^e together represent (=0) or R^' represents hydrogen and R^e represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=O)OR^S or CH₂C(=0)NR^mRⁿ, wherein each (CrC₆)alkanoyloxy is optionally substituted with one or more NR*R^U; each of Rf and RS is independently hydrogen, (Cj-C₆)alkyl or (C₁-C₆)alkanoyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or Rf and R§ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RJ and R^k is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or RJ and R^k together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of R^m and Rⁿ is independently hydrogen or (CrC₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR^R^U; or R^m and Rⁿ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of Rl, R^, and R^ is independently hydrogen (C]-C₆)alkyl, (CrC₆)alkoxy, aryl or heteroaryl wherein each (Ci-C₆)alkyl and (Ci-C₆)alkoxy is optionally substituted with OH, (C₁-

C₆)alkoxy, (C_rC₆)alkylthio, aryl, NR⁰RP, or -C(=O)NRqR^r; and wherein each aryl or heteroaryl is optionally substituted with one or two substituents selected independently from a halogen atom and (d-C₄)alkyl wherein (Ci-C₄)alkyl is optionally substituted with NR⁰RP; each of R⁰ and RP is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or R⁰ and RP together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RI and R^r is independently hydrogen or (CrC₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NRtR^u; or RQ and R^r together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring;

R^s is hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR^lR^u; and each of Rt and R^u is independently hydrogen, (d-C₆)alky or (Ci-C₆)alkanoyl; or R¹ and R^u together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino. morpholino, thiomorpholino, or azepino ring; or a salt thereof. The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.

Additionally, the invention provides a therapeutic method for treating cancer comprising administering to a mammal (e.g., a human male or female) in need of such therapy, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medical therapy (e.g., for use in treating cancer), as well as the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment of cancer in a mammal, such as a human. The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the prophylactic or therapeutic treatment of cancer.

The invention also provides processes and intermediates disclosed herein that are useful for preparing compounds of formula (I) or salts thereof.

Detailed Description

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl denotes an aromatic heterocyclic ring containing 5 or 6-ring members including from one to four ring hetero atoms selected from oxygen, sulfur and nitrogen, the remainder being carbon, which ring is optionally ortho-fused to a benzene ring or another 5- or 6-membered heteroaromatic ring. It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

Unless otherwise indicated, the divalent groups A and B, can have either of their two possible orientations (forward or reversed) in the compounds of formula (I) and other ring systems disclosed herein. For example, when A represents -CH(R^a)NHC(=O)-, this group may have the orientation -CH(R^a)NHC(=O)- or -(O=C)NHCH(R^a)-.

In cases where R^ and R^c together represent a bond, the resulting bond between CH(R") and CH(R^C) is a double bond.

In cases where R"' and R^c' together represent a bond, the resulting bond between CH(R^b') and CH(R^C') is a double bond.

Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Specifically, (Ci-C₆)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec- butyl, pentyl, 3-pentyl, or hexyl; (C₂-C₆)alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1- hexenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (Cj-C₆)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (Ci-C₆)alkanoyl can be acetyl, propanoyl or butanoyl; and aryl can be phenyl, indenyl, or naphthyl. Heteroaryl can be pyridyl.

In one embodiment, the compounds of formula (I) include

(I)

wherein: one of A and B is -CH(R^b)CH(R^c)C(R^d)(R^e)-; and the other of A and B is:

; -CH(R^a)NHC(=O)- or -CH(R^b')CH(R^c')C(R^d')(R^e')-; one of F and G is X and the other is C(R^); each X is independently NH, S, or O; the dotted line in the ring containing F and G signifies that two double bonds are present in the ring, the positions of which depend upon the values selected for F and G; n and n' each independently represents 1, 2, 3, 4 and 5, provided that the sum of n and n' is 6;

R^a represents hydrogen, (Ci-C₆)alkyl, (CrC₆)alkoxy or (Ci-C₆)alkanoyloxy, wherein each (Ci-C₆)alkyl, (Ci-C₆)alkoxy and (d-C₆)alkanoyloxy, is optionally substituted with OH,

(Ci-C₆)alkoxy, (Ci-C₆)alkylthio, aryl, heteroaryl, NR^fR§ or

and wherein each aryl and heteroaryl is optionally substituted with one or two substituents selected independently from halo, (Ci-C₆)alkyl, NR^fRg and NRfRg(C _rC₆)alkyl- R^ and R^c each represents hydrogen, or R^ and R^c together represent a bond or -O-;

Rd and R^e together represent (=0) or Rd represents hydrogen and R^e represents hydrogen, hydroxy, (Q-C^alkanoyloxy, NRJR^k, CH₂C(=O)OR^S or CH₂C(=0)NR^mRⁿ, wherein each (Ci-C₆)alkanoyloxy is optionally substituted with one or more NR*R^U;

R^' and R^c' each represents hydrogen, or R^' and R^c'together represent a bond or -O-; Rd and R^e together represent (=0) or Rd' represents hydrogen and R^e represents hydrogen, hydroxy, (d-C₆)alkanoyloxy, NRJR^k, CH₂C(=0)0R^s or CH₂C(=O)NR^mRⁿ, wherein each (C]-C₆)alkanoyloxy is optionally substituted with one or more NR*R^U; each of Rf and RS is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or Rf and RS together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RJ and R^k is independently hydrogen or (Ci-C₆)alkyl, which (C]-C₆)alkyl is optionally substituted with one or more NR*R^U; or RJ and R^k together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of R^m and Rⁿ is independently hydrogen or (Cj-C₆)alkyl, which (C]-C₆)alkyl is optionally substituted with one or more NR*R^U; or R^m and Rⁿ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RI , R^, and R^ is independently hydrogen, (CrC₆)alkyl, (Ci-C₆)alkoxy , aryl or heteroaryl wherein each (Ci-C₆)alkyl and (Ci-C₆)alkoxy is optionally substituted with OH,

(Ci-C₆)alkoxy, (Ci-C₆)alkylthio, aryl, NR⁰RP, or -C(=O)NRqR^r; and wherein each aryl or heteroaryl is optionally substituted with one or two substituents selected independently from a halogen atom and (Ci-C₄)alkyl wherein (Ci-COalkyl is optionally substituted with NR⁰RP; each of R° and RP is independently hydrogen or (C]-C₆)alkyl, which (d-C₆)alkyl is optionally substituted with one or more NR^R¹¹; or R⁰ and RP together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each OfR⁰I and R^r is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or RI and R^r together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring;

R^s is hydrogen or (d-C₆)alkyL which (Ci-C₆)alkyl is optionally substituted with one or more NR¹R¹¹; and each of R¹ and R^u is independently hydrogen, (Ci-C₆)alkyl or (C₁-C₆)alkanoyl, or R¹ and R^u together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring. or a salt thereof. In one embodiment, the compounds of formula (I) have the structure (F):

(I') In another embodiment, they have the structure (I"):

(I")

An example of a particular value for each X in the compounds of formulae (I) is O. An example of a value for A when it represents

is

An example of a value for R.3 is hydrogen.

Examples of values for A when it represents -CH(R^a)NHC(=0> are -CH2NHC(=0)-, - CH(CH₃)NHC(=O)-, -CH(CH(CH3)2)NHC(=O)-, -CH(CH(CH3)(CH2CH₃))NHC(=O)-, -CH(CH₂C H(CH₃)₂)NHC(=O)-, and -CH(CH₂Ph)NHC(O)-. Examples of particular values for R^a are hydrogen, methyl, isopropyl, 1-methylpropyl, 2- methylpropyl, benzyl, 4-hydroxybenzyl, 4-iodobenzyl, 4-aminobenzyl, and A-(2-N,N- dimethylaminoethylamino)benzyl, more particularly methyl, isopropyl, 1 -methylpropyl, 2- methylpropyl and benzyl.

Examples of particular values for R^a are (C₁-Ce)alkyl or (C₂-C₆)alkenyl wherein each (CrC₆)alkyl, and (C₂-C₆)alkenyl, is optionally substituted with NR^RS.

Examples of particular values for R^a are aminomethyl, 2-aminoethyl, 3-aminopropyl or 4-aminobutyl.

Examples of particular values for A when it represents -CH(R^b')CH(R^c')C(R^d')(R^e')- are -CH=CH-CH₂- , -CH=CH-CH(OH)-, -CH=CH-CH(CH₂CON(CH₃)₂))- and -CH=CH- CH(CH₂CO₂CH₃)-

Exarnples of particular values for Rt*' and R^c' are, together are a bond.

An example of a particular value for R^d' is hydrogen.

Examples of particular values for R^e' are hydrogen, hydroxy, CH₂C(=O)OCH₃, CH₂C(=O)N(CH₃)₂, and CH₂C(=O)NHCH₂CH₂N(CH₃)₂. Examples of values for B are - CH=CH-CH₂- , -CH=CH-CH(OH)-, -CH=CH-CH(CH₂CON(CH₃)₂)> and -CH=CH-CH(CH₂CO₂CH₃)-.

Examples of particular values for R^b and R^c are, together are a bond. An example of a particular value for R^d is hydrogen.

Examples of particular values for R^e are hydrogen, hydroxy, CH₂Q=O)OCH₃, CH₂C(=O)N(CH₃)₂, and CH₂C(=O)NHCH₂CH₂N(CH₃)₂.

A particular value for Rl is hydrogen. A particular value for R^ is hydrogen.

Examples of compounds of formula (I) are compounds of formulae:

(Ia')

(Ia")

(Ib')

(Ib")

10

(Ic')

(Id')

(Ie") and

(If) in which:

R¹, R², R^a, R^b, R^c, R^d, R^e, R^b', Re', Rd' and Re' have any of the meanings described hereinabove.

A particular value, for R Hs hydrogen; and for R² is hydrogen.

Additional examples of compounds of formula (I) are compounds of formulae:

(Ig') and

(Ih')

in which:

R¹, R², R^a, R^b, R^c, R^d, R^e, R^b', R^c', R^d' and Re' have any of the meanings described hereinabove.

A particular value for R^a is alkyl, for R^ is hydrogen and for R² is hydrogen. A particular value for R^a is also (Ci-C₆)alkyl or (C₂-C₆)alkenyl wherein each (Ci- C₆)alkyl, and (C₂-C₆)alkenyl, is optionally substituted with NR^fR^§.

A particular value for R^a is also aminomethyl, 2-aminoethyl, 3-aminopropyl or 4- aminobutyl.

The compounds of formula (I) can be prepared by forming an intermediate comprising a linear chain of the requisite polyazoles, olefin and peptide/olefin, or a protective derivative thereof, then cyclizing this by olefin metathesis or by using the Heck coupling reaction, and optionally derivatizing one or more olefin groups, removing any protecting groups and optionally forming a salt.

Examples of representative synthetic routes to compounds of formula (I) are provided in Schemes 1 to 6 below. Although R¹, R², and R³ are hydrogen in the illustrated compounds, these or similar synthetic routes can also be used to prepare other compounds wherein R¹, R², and R^J have other values. Scheme 1 Preparation of Macrocyclic Azoles via Condensation and Metathesis

Scheme 2 Preparation of Macrocyclic Azoles via Heck Coupling and Metathesis

Scheme 3

"Normal" Heck Coupling

Scheme 4 'Normal" Metathesis

Scheme 5

'Reversed" Heck Coupling

Isomer of Metathesis p rod uct

Scheme 6 "Reversed" Metathesis

I) HMDS

₂C=CHSnBu₃

Grubb's, CH₂CI₂, rt

Additional examples of representative synthetic routes to compounds of formula (I) are provided in Scheme 7 below.

Scheme 7

BocHN n = 1 ,2,3

CbzHN CO₂H

THF step 1)

In cases where compounds are sufficiently basic or acidic, a salt of a compound of formula I can be useful as an intermediate for isolating or purifying a compound of formula I. Additionally, administration of a compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, α- ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made. The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, e.g., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.

Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices. The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), a vegetable oil, a nontoxic glyceryl ester, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compounds may be applied in pure form, e.g., when they sire liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compounds of formula (I) to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compounds of formula (I) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949. Generally, the concentration of the compound(s) of formula (I) in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g.. from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.

The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

Compounds of the invention can also be administered in combination with other therapeutic agents, for example, other agents that are useful for the treatment of cancer. Accordingly, in one embodiment the invention also provides a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, at least one other therapeutic agent, and a pharmaceutically acceptable diluent or carrier. The invention also provides a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, at least one other therapeutic agent, packaging material, and instructions for administering the compound of formula I or the pharmaceutically acceptable salt thereof and the other therapeutic agent or agents to an animal to treat cancer.

The ability of a compound of the invention to stabilize G-quadroplex DNA may be determined using pharmacological models which are well known to the art, or using Test A described below.

Test A. Stabilization of G-quadruplex DNA

Analyses can be performed to determine the ability of the agents to bind and thermally stabilize the duplex, triplex, and quadruplex forms of nucleic acids. Toward this end, the UV absorbances of the nucleic acids as a function of temperature in the absence and presence of HXDV is monitored. The melting of duplex and triplex nucleic acids is generally associated with a hyperchromic shift at 260 nm, while the melting of quadruplex nucleic acids is associated with a hypochromic shift at 295 nm. Thus, the temperature-dependent absorbances of duplexes and triplexes is monitored at 260 nm, with corresponding quadruplex absorbances being monitored at 295 nm. ST DNA, p(rA>p(rU), p(rA>p(dT), p(dA>2p(dT), p(rA>2p(rU), d(T AG ) , and r(UG U) is used as representative models of a DNA duplex, an RNA duplex, a hybrid DNA^»RNA duplex, a DNA triplex, an RNA triplex, a DNA quadruplex, and an RNA quadruplex, respectively. All the UV melting studies are conducted at pH 7.5 in the presence of potassium ions. The ability of compounds to stabilize G-quadroplex DNA may also be determined using

Test B described below.

Test B. Temperature-dependent spectrophotometry

Temperature-dependent absorption experiments are conducted on an AVIV Model 14DS

Spectrophotometer (Aviv Biomedical, Lakewood, NJ) equipped with a thermoelectrically controlled cell holder. Quartz cells with a pathlength of 1.0 cm are sed for all the absorbance studies. Temperature-dependent absorption profiles are acquired at either 260 (for duplex and triplex) or 295 (for quadruplex) nm with a 5 sec averaging time. The temperature is raised in 0.5 ⁰C increments, and the samples are allowed to equilibrate for 1.5 min at each temperature setting. In the quadruplex melting studies, the concentrations of d(T 2 AG 3 ) 4 , 9AP, 15AP, and 21 AP are 5 μM in strand (120 μM in nucleotide), while the concentration of r(UG U) is 20 μM in strand (120 μM in nucleotide). In the duplex and triplex melting studies, the nucleic acid concentration is 15 μM in base pair (30 μM in nucleotide) or 15 μM in base triple (45 μM in nucleotide) and the HXDV concentration, when present, is 15 μM. The buffer for all the UV melting experiments contains 10 mM EPPS (pH 7.5). In addition, sufficient KCl is added to

+ each solution to bring the total K concentration to either 150 mM for d(T AG ) and p(rA>p(dT), 2 mM for T(UG₄U)₅ 50 mM for ST DNA, 250 mM for p(dA>2p(dT), or 20 mM for p(rA)*2p(rU). Prior to their use in UV melting experiments, all nucleic acid solutions are preheated ait 90 ⁰C for 5 min and slowly cooled to room temperature over a period of 4 hr.

The anti-proliferative activity of a compound of the invention may be determined using pharmacological models which are well known to the art, or using Test C described below.

Test C. Evaluation of G-quadruplex stabilizers using the MTT assay.

Cell lines are selected based upon one or more factors including data on their relative telomerase activity, varied organ sites, available comparative data, and their ability to form solid tumors in athymic nude mice. The advantage of an MTT assay is that the cytotoxic/cytostatic activities can be readily determined. Cells are cultured for 4 days at 37 ⁰C followed by addition of MTT (3-[4,5-dimethylthiozol-2-yl]-2,5-diphenyltetrazolium bromide (Sigma) (0.1 mg/ml). Cells are treated with MTT for 3 hrs and then dissolved in 100 μl 100% DMSO. Absorbance is measured at OD_57O using a microplate reader (Model 3550 UV from BIO-RAD). The MTT value is normalized to ODs_7O of cells treated with Cellfectin alone. Stock solutions of each compound are prepared. MTT assays are performed using spectrometric analysis and 96 well plates. Compound 258, a representative compound of formula 1, was evaluated against a variety of cell lines using the MTT assay compound. Compound 258 displays potent cytotoxic activity against murine leukemia P388 (IC_5O = 45 nM), human lymphoblastoma RPMI 8402 (IC₅₀ ⁼ 25 nM) and human nasopharyngeal carcinoma KB3-l(ICso = 25 nM).

The following non-limiting examples illustrate the preparation of compounds of formula (I) as well as synthetic intermediates useful for the synthesis of compounds of formula (I). Example 1. Preparation of Representative Compounds of the Invention

Using procedures similar to those described herein, the following representative compounds of the invention can be prepared.

Example 2. Preparation of Representative Compounds of the Invention

Using procedures similar to those described herein, the following representative compounds of the invention can be prepared.

Example 3. Preparation of Teroxazole Intermediate A teroxazole intermediate that can be used to prepare compounds of the invention can be prepared as follows.

a. Synthesis of Compound 206 (N-Boc Valine Amide)

Dr> acetonitrile (100 mL) was added to a mixture of N-Boc-L-valine (2.17 g, 10 mmol) and serine methyl ester hydrochloride (1.86 g, 12 mmol) and stirred for 5 min. BOP (4.42 g, 10 mmol) and triethylamine (3.1 mL, 22 mmol) were added and the mixture was stirred at room temperature for 12 h. The mixture was then evaporated under reduced pressure and diluted with EtOAc and. brine. The phases were separated and then aqueous phase was extracted with EtOAc. The combined organic phases were then washed successively with IN HCl, saturated NaHCO₃, and brine and then dried over Na₂SO₄, filtered and evaporated to give the amide as a colorless oil, 3.18 g (100%); ¹H NMR (CDCl₃) δ 7.45 (dd, IH, J=1.4), 5.58 (d, IH, J=8.8), 4.45 (m, IH), 4.37 (m, IH), 3.79 (m, 2H), 3.54 (s, 3H), 1.88 (m, IH), 1.23 (s, 9H), 0.74 (d, 6H, J=6.6); ¹³C-NMR δ 172.3, 171.0, 162.9, 156.0, 79.4, 62.3, 54.6, 52.3, 31.3, 28.2, 17.7, 17.4.

b. Synthesis of Compound 207 (N-Boc Valine Oxazoline)

A solution of 206 (2.54 g, 8 mmol) in CH₂Cl₂ (16 mL) was cooled to -78 ⁰C under nitrogen and treated with DAST (1.7 mL, 13.2 mmol). After stirring for 1.5 h anhydrous K₂CO₃ (1.32 g) was added and the mixture was then allowed to warm to room temperature. The mixture was poured into saturated NaHCO₃ and extracted several times with CH₂Cl₂. The combined extracts were dried over Na₂SO₄, filtered and concentrated to give oxazoline 207 as a red-yellow oil, 2.36 g (98%, crude); ¹H NMR (CDCl₃) δ 5.12 (d, IH, J=8.4), 4.70 (m, IH), 4.41 (m, 3H), 3.74 (s, 3H), 2.02 (m, IH), 1.24 (s, 9H), 0.74 (d, 6H, J=6.6); ¹³C-NMR δ 171.3, 169.5, 155.5, 79.6, 69.8, 67.8, 54.1, 52.6, 31.8, 28.3, 17.7, 17.3.

c. Synthesis of Compound 208 (N-Boc Valine Oxazole)

A solution of the crude oxazoline (2.36 g, 7.9 mmol) in dry CH₂Cl₂ (24 mL) was stirred under nitrogen at 0 ⁰C as dry DBU (1.8 mL, 12.5 mmol) was added over 2 min followed by BrCCl₃ (1.2 mL, 12.5 mmol) which was then added over 5 min. The reaction was stirred at 0 ⁰C for 5 h and was then poured into saturated NH₄Cl. The mixture was extracted with CH₂Cl₂ and the combined extracts were dried over Na₂SO₄, filtered, and evaporated. The product was purified b> flash chromatography on silica gel eluting with 2:3 EtOAc/hexane to give the oxazole as a white solid, 2.36 g (75%); mp 125-129 ⁰C; ¹H NMR (CDCl₃) δ 8.1 (s, IH), 5.31 (d, IH, J=9.2), 4.63 (dd, IH, J=9,6), 3.73 (s, 3H), 2.04 (m, IH), 1.25 (s, 9H), 0.74 (d, 6H, J=6.6); ¹³C NMR δ 165.0, 161.5, 155.3, 143.9, 133.0, 79.7, 54.2, 52.0, 32.8, 28.2, 18.6, 17.9.

d. Synthesis of Compound 209 (N-Boc Valine Oxazole Carboxylic Acid)

A solution of the ester (0.8 g, 2.68 mmol) in 3:1 THF/H₂O (32 mL) was stirred at 0 ⁰C as LiOH (134 mg, 3.19 mmol) was added in one portion. The reaction mixture was stirred for 1O h and was then evaporated under reduced pressure to remove THF. The aqueous solution was brought to pH 3 with IN HCl and was then extracted with EtOAc. The organic phase was washed with brine and dried over Na₂SO₄, filtered and evaporated to give the carboxylic acid as a white solid, 0.67 g (88%); mp 157-160 °C; ¹H NMR (CDCl₃) δ 8.2 (s, IH), 6.34 (d, IH, J=8.4), 4.78 (t, IH, J=8.3), 2.16 (m, IH), 1.33 (s, 9H), 0.87 (dd, 6H, J=I 4,7); ¹³C NMR δ 166.4, 163.9, 155.9, 144.3, 133.8, 79.9, 54.6, 32.8, 28.3, 18.8, 18.3.

e. Synthesis of Compound 210 (N-Boc Valine O-Benzyl Bisoxazole Amide)

e

Dry acetonitrile (100 mL) was added to a mixture of amine 204 (3.24 g, 11.7 mmol) and acid 209 (3.33 g, 11.7 mmol) and stirred for 5 min. BOP (5.17 g, 11.7 mmol) and triethylamine (3.6 mL, 25.7 mmol) were added and the mixture was stirred at room temperature for 12 h. The mixture was then evaporated under reduced pressure and diluted with EtOAc and brine. The phases were separated and then aqueous phase was extracted with EtOAc. The combined organic phases were then washed successively with IN HCl, saturated NaHCO₃, and brine and then dried over Na₂SO₄, filtered and evaporated to give the amide as a colorless oil, 4.76 g (90%); ¹H NMR (CDCl₃) δ 8.34 (s, IH), 8.22 (s, IH), 7.91 (d, IH, J=8.4), 7.42 (m, 5H), 5.73 (m, IH), 5.53 (m, IH), 4.87 (m, IH), 4.68 (s, 2H), 4.18 (m, 2H), 4.01 (s, 3H), 2.28 (m, IH), 1.58 (s, 9H), 1.08 (d, 3H, 3=6.6), 1.04 (d, 3H, J=7.0); ¹³C-NMR δ 163.2, 161.9, 161.8, 160.5, 159.5, 154.5, 143.4, 140.6, 136.4, 134.4, 132.5, 127.5, 126.9, 126.7, 79.1, 72.2, 68.9, 53.4, 51.2, 46.4, 31.7, 27.4, 17.9, 17.2.

f. Synthesis of Compound 211 (N-Boc Valine Serine Amide)

A solution of benzyl ether 9 (5.72 g, 10.6 mmol) in 95% EtOH (75 mL) was treated with 20% Pd(OHVC (572 mg) and shaken in a Parr apparatus under 35 psi H₂ for 30 h at room temperature. The catalyst was filtered through a pad of Celite and the solvent was evaporated to give the alcohol as a colorless oil, 4.54 g (95%); ¹H NMR (CDCl₃) δ 8.69 (d, IH, J=8.2), 8.36 (s, IH), 8.29 (s, IH), 6.19 (d, IH, J=6.2), 5.66 (m, IH), 4.77 (m, IH), 4.33 (m, 2H), 3.97 (s, 3H), 2.25 (m, IH), 1.55 (s, 9H), 1.04 (d, 3H, 3=6.6), 0.89 (d, 3H, 3=6.6); ¹³C-NMR δ 163.2, 162.9, 161.9, 160.7, 160.5, 160.4, 154.7, 143.5, 140.9, 140.5, 134.2, 132.1, 127.4, 79.2, 61.7, 53.4, 51.4, 49.1, 48.3, 31.7, 30.8, 27.4, 18.2, 17.9, 17.3, 17.1.

g. Synthesis of Compound 212 (N-Boc Valine Dihydroteroxazole)

A solution of 211 (4.54 g, 10 mmol) in CH₂Cl₂ (20 mL) was cooled to -78 ⁰C under nitrogen and treated with DAST (2.17 mL, 16.6 mmol). After stirring for 1.5 h anhydrous K₂CO₃ was added and the mixture was then allowed to warm to room temperature. The mixture was poured into saturated NaHCO₃ and extracted several times with CH₂Cl₂. The combined extracts were dried over Na₂SO₄, filtered and concentrated to give crude oxazoline 212 as a red- yellow foam, 3.44 g (79%, crude); ¹H NMR (CDCl₃) δ 8.30 (s, IH), 8.18 (s, IH), 5.59 (m, 2H), 4.84 (m, 3H), 3.91 (s, 3H), 2.19 (m, IH), 1.42 (s, 9H), 0.91 (d, 6H, J=6.8); ¹³C-NMR δ 164.4, 162.1, 162.0, 160.3, 159.2, 154.3, 143.9, 140.7, 132.3, 128.7, 78.7, 69.7, 53.2, 51.2, 31.9, 27.2, 17.7, 16.9. h. Synthesis of Compound 213 (N-Boc Valine Teroxazole Ester)

A solution of the crude oxazoline (3.44 g, 7.9 mmol) in dry CH₂Cl₂ (24 rnL) was stirred under nitrogen at O ⁰C as dry DBU (1.8 mL, 12.5 mmol) was added over 2 min followed by

BrCCl₃ (1.2 mL, 12.5 mmol) which was then added over 5 min. The reaction was stirred at 0 °C for 5 h and was then poured into saturated NH₄Cl. The mixture was extracted with CH₂Cl₂ and the combined extracts were dried over Na₂SO₄, filtered, and evaporated. The product was purified by flash chromatography on silica gel eluting with 2:3 EtOAc/hexane to give the oxazole as a white solid, 1.64 g (48%); mp 214-224 ⁰C; ¹H NMR (CDCl₃) δ 8.58 (s, IH), 8.48

(s, IH), 8.46 (s, IH), 5.53 (d, IH, J=9.0), 4.95 (m, IH), 4.08 (s, 3H), 2.35 (m, IH), 1.56 (s, 9H),

1.07 (d, 6H. 3=6.6); ¹³C NMR δ 164.8, 160.4, 154.5, 143.1, 138.5, 133.4, 129.9, 128.7, 79.1,

53.4, 51.4, 31.9, 27.4, 17.8, 17.1.

i. Synthesis of Compound 214 (N-Boc Valine Teroxazole Carboxylic Acid)

A solution of the ester (0.82 g, 1.9 mmol) in 3:1 THF/H₂O (32 mL) was stirred at 0 ⁰C as LiOH (126 mg, 3 mmol) was added in one portion. The reaction mixture was stirred for 1O h and was then evaporated under reduced pressure to remove THF. The aqueous solution was brought to pH 3 with IN HCl and was then extracted with EtOAc. The organic phase was washed with brine and dried over Na₂SO₄, filtered and evaporated to give the carboxylic acid as a white solid, 0.77 g (98%); mp 225 ⁰C (dec); ¹U NMR (CDCl₃) δ 8.44 (s, IH), 8.39 (s, IH), 8.32 (s, IH), 5.39 (d, IH, J=8.4), 4.85 (m, IH), 2.25 (m, IH), 1.44 (s, 9H), 0.95 (d, 6H, J=6.0); ¹³C NMR δ 164.8, 160.4, 154.5, 143.1, 138.5, 133.4, 129.9, 128.7, 80.1, 51.4, 31.9, 27.4, 17.8, 17.1. Synthesis of Compound 215 (Amino Valine Teroxazole Ester)

A solution of the N-Boc derivative (0.82 g, 1.9 mmol) in CH₂Cl₂ (10 mL) was cooled to 0 ⁰C under protection from moisture by a drying tube. TFA (10 mL) was added and the solution was stirred for 1.5 h. Solvents were evaporated under reduced pressure and residual TFA was removed as an azeotrope with benzene. The residue was taken up in CH₂Cl₂ and washed with saturated NaHCO₃ and was then dried over Na₂SO₄, filtered, and evaporated to give the amine as a yellow-white solid, 0.62 g (98%); ¹H NMR (CDCl₃) δ 8.52 (s, IH), 8.42 (s, 2H), 3.98 (s, 3H), 3.90 (m, IH), 2.34 (m, IH), 0.97 (d, 6H, J=6.6); ¹³C-NMR δ 163.5, 160.2, 155.1, 154.4, 154.1, 142.9, 138.6, 138.4, 133.4, 129.8, 128.8, 55.8, 51.9, 33.4, 18.9, 17.8.

The intermediate 204 can be prepared as follows. k. Synthesis of Compound 201

201

Boc-O-benzyl-L-serine (4.13g, 14mmol), serine methyl ester (2.18g, 14mmol) and BOP (6.19 g, 14mmol) were dissolved in CH₃CN (40 mL). Then triethylamine (4.2mL, 30.8mmol, 2.2eq) was added. The reaction stirred overnight at room temperature. The solvent was removed and the residue was dissolved in CH₂Cl₂ and washed successively with brine, 2N HCl, 0.5N NaHCO₃, water and brine. The organic extract was dried over Na₂SO₄ and concentrated to a clear oil weighing 5.54g, 100%. ¹H NMR (CDCl₃) δ 7.31 (s, 6H), 5.49 (d, IH, J = 6), 4.64 (m, IH), 4.55 (s. 2H), 4.31 (m, IH), 3.88 (dd, IH J = 5, 10), 3.75 (s, 3H), 3.63 (dd, IH J = 6, 10), 2.96 (br s, IH), 1.44 (s, 9H). ¹³C NMR (CDCl₃) δ 170.5, 170.3, 155.5, 137.2, 128.3, 127.8, 127.8, 127.7, 80.5, 73.3, 69.8, 69.4, 62.6, 62.4, 60.3, 54.8, 52.5, 28.1. IR (thin film NaCl) 3419, 3065, 3032, 2979, 2954, 2871, 2251, 1670, 1498, 1455, 1439, 1392, 1368, 1248, 1167, 1105, 1027 cm^"1. HRMS (FAB) m/z calcd for Cj₉H₂₈N₂O₇Li (M + Li) 403.2057; found, 403.2052.

I. Synthesis of Compound 202 (serine oxazoline)

Compound 201 (5.54g, 14 mmol) was dissolved in CH₂Cl₂ (2OmL) and placed under argon. After cooling to -78 ⁰C, DAST (2.8mL 21.4mmol, 1.5eq) was added and the reaction stirred at low temperature for 2.5 hours. Then K₂CO₃ 2.9 g, 21.4 mmol, 1.5eq) was added and the reaction warmed to room temperature. This was poured into saturated NaHCO₃. The layers were separated and the aqueous was extracted with CH₂Cl₂. The organic extracts were dried over Na₂SO₄ and concentrated to an orange oil weighing 5.28g, 99%. ¹H NMR (CDCl₃) δ 7.50 (m, 5H), 5.66 (m, IH), 4.99 (dd, IH, J = 8, 10), 4.71 (m, 5H), 3.96 (m, 5H), 1.64 (s, 9H). ⁾³C NMR (CDCl₃) δ 170.2, 167.4, 154.3, 136.9, 134.2, 127.5, 126.8, 126.6, 79.0, 72.2, 69.2, 69.0, 67.2, 67.1, 52.5, 51.7, 48.5, 24.7. IR (neat NaCl) 3384, 3063, 3030, 2977, 2870, 1709, 1666, 1506, 1454, 1367, 1322, 1166, 1109, 1051 cm^"1.

m. Synthesis of Compound 203 (Boc-O-benzyl serine oxazole)

203

Oxazoline 202 (5.28g, 14mmol) in CH₂Cl₂ (2OmL) was placed under argon and cooled to

0 ⁰C. DBU (3.2 mL, 2mmol, 1.6eq) was added dropwise and the solution turned yellow. Then BrCCl₃ (2.2mL, 22.4mmol) was added dropwise and the solution became brown. This warmed to room temperature overnight and then poured into saturated ammonium chloride. The aqueous layer was extracted with CH₂Cl₂. The organic layers were dried over Na₂SO₄ and concentrated to a brown oil. This was flash chromatographed on SiO₂ with 15-50% EtOAc/hexane. The product was obtained as a clear oil 3.10g, 59%. [α]²⁵ _D -33.35 (c = 2g/100mL in EtOH). ¹H NMR (CDCl₃) δ 8.36 (s, IH) 7.41 (m, 5H), 5.76 (d, IH, J = 8), 5.30 (m, IH), 4.66 (s, 2H), 4.07 (m, 3H), 3.97 (m, 2H), 1.61 (s, 9H). ¹³C NMR (CDCl₃) δ 163.4, 161.3, 154.9, 144.0, 137.2, 133.3, 128.2, 127.7, 127.4, 80.1, 73.1, 70.3, 52.0, 49.2, 28.1. IR (thin film NaCl) 3351, 3163, 3064, 3031, 2978, 2953, 2870, 2251, 1717, 1585, 1499, 1454, 1439, 1392, 13677, 1324, 1251, 1202, 1168, 1112, 1047, 1001 cm^"1.

n. Synthesis of Compound 204

204

The Boc-protected serine oxazole (3.64 g, 9.68 mmol) was dissolved in dry CH₂Cl₂ (10 niL) and cooled to 0°C. This solution was treated with TFA (10 niL) and stirred for 6.5 hours. Solvent was removed in vacuo under aspirator pressure. Resulting dark brown residue was azeotroped with benzene (x 2) and then dissolved in CH₂Cl₂ and poured into saturated sodium bicarbonate. Extracted with CH₂Cl₂ (4 x 15 mL). The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated to a dark brown oil (2.65 g, 99% isolated yield). ¹H NMR (CDCl₃) δ 8.19 (s, IH), 7.31 (m, 5H), 4.54 (s, 2H), 4.30 (m, IH), 3.92 (s, 3H), 3.80 (dd, 2H, J = 4.4, 9.5 Hz), 1.64 (br s, 2H); ¹³C NMR (CDCl₃) δ 170.2, 167.6, 143.2, 136.8, 132.4, 127.6, 126.9, 126.8, 72.5, 71.6, 51.3, 49.5; IR (neat) 3378, 3308, 3160, 3030, 2952, 2865, 1740 cm ^"'.

Example 4. Synthesis of compound 258

258

Methyl 3-hydroxy-2-(oxazole-4-carboxamido)propanoate(244). Oxazole-4- carboxylic acid (3.88 g, 34.4 mmol), serine methyl ester (5.35 g, 34.4 mmol), EDC (13.2 g, 68.8 mmol) and HOBT (9.31 g, 68.8 mmol) were dissolved in dry DMF (100 niL) and placed under argon and 2,6-lutidine (2.8 mL, 172 mmol) was then added. The reaction was stirred at room temperature overnight after which solvent was removed by Kugelrohr distillation (50 °C, 5 mm Hg). The residue was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed sequentially with saturated sodium bicarbonate, 5% HCl, and brine. The extract was dried with Na₂SO₄ and evaporated under reduced pressure to give a white solid, 6 g, 81%; mp 87-89 ⁰C; ¹H NMR (CDCl₃) δ 4.52 (d, IH, J=Ll), 7.86 (m, 2H), 4.84 (dt, IH, J=3.7, 8.1), 4.55 (br s, IH), 4.06 (ddd, 2H, J=4, 8.8, 11.4) 3.8 (s, 3H); ¹³C NMR (CDCl₃) δ 669.6, 159.8, 149.9, 141.1, 134.5, 125.7, 125.4, 1 16.4, 110.2, 62.1, 53.6, 51.9; IR (Nujol) 3419, 3379, 3189, 3160, 3140, 1753, 1650, 1638, 1594, 1508, 1376, 1282, 1226, 1182, 1131, 1109, 1065, 1034, 969, 897, 887, 859, 822, 766, 741, 604 cm^"1; HRMS (ESI) m/z calculated for C₈Hj₀N₂O₅Na (M+Na) 237.0487; found 237.0487.

Methyl 2-(oxazol-4-yl)-4,5-dihydrooxazole-4-carboxylate(245). The amide 244 (6 g,

28 mmol) was dissolved in anhydrous CH₂Cl₂ and placed under argon. After cooling to -78 ⁰C, DAST was added (6.4 niL, 49 mmol) and the reaction stirred at low temperature for 4 h. Solid K₂CO₃ (6.77 g, 49 mmol) was then added and the reaction was warmed to room temperature. The reaction mixture was poured into saturated sodium bicarbonate solution and extracted with CH₂Cl₂. The organic extracts were dried with Na₂SO₄ and concentrated in vacuo to an orange oil weighing 3.72 g, 65%; ¹H NMR (CDCl₃) 5 8.19 (s, IH), 8.03 (s, IH), 4.95 (dd, IH, J=8, 11), 4.65 (m, 2H), 3.75 (s, 3H); ¹³C NMR (CDCl₃) δ 170.3, 159.4, 151.4, 140.7, 128.5, 69.4, 66.9, 51.8; IR (Thin film NaCl) 3655, 3408, 3227, 3150, 2997, 2957, 2910, 2849, 2244, 2197, 1740, 1678, 1583, 1561, 1518, 1439, 1392, 1314, 1218, 1135, 1104, 1065, 981, 962, 935, 915, 844, 731, 650, 607, 558 cm^"1.

Methyl 2,4'-bioxazole-4-carboxyIate(246). A solution of the oxazoline 245 (3.72 g, 19 mmol) in anhydrous CH₂Cl₂ was cooled to 0 ⁰C under argon and treated dropwise with DBU (5.7 mL, 38 mmol) and then BrCCl₃ (5.2 mL, 53.2 mmol) both over a period of 10 min. This was stirred and allowed to warm to room temperature overnight. The reaction mixture was poured into saturated ammonium chloride and extracted with CH₂Cl₂. After drying with Na₂SO₄, the organic solution was evaporated to a brown solid that was purified by flash chromatography on SiO₂ eluting with 100% CHCl₃ to 2% MeOH/CHCl₃. The product was obtained as a white solid, 2.77 g (75%); mp 177 ⁰C; ¹H NMR (CDCl₃) δ 8.44 (d, IH, J=0.73), 8.34 (s, IH), 8.05 (s, IH), 3.96 (s, 3H); ¹³C NMR (CDCl₃) δ 160.5, 154.7, 151.1, 143.0, 138.9, 133.4, 128.7, 51.5; IR (NuJoI) 3152, 3124, 2729, 1714, 1633, 1572, 1536, 1512, 1377, 1327, 1305, 1273, 1203, 1149, 1123, 1093, 1062, 999, 953, 917, 905, 849, 809, 775, 735, 668 cm^"1; HRMS (ESI) m/z calculated for C₈H₆N₂O₄Na (M+Na) 217.0225; found 217.0226.

2,4'-Bioxazole-4-carboxylic acid(247). A solution of the bis(oxazole) ester 246 (2.77 g, 14.2 mmol) in a 3:1 mixture of THF and water (200 mL) was cooled to 0 ⁰C and treated with LiOH (721 mg, 17.2 mmol). The reaction was stirred and allowed to warm to room temperature overnight. The THF was removed under reduced pressure and the aqueous solution was treated with Amberlyst A- 15 resin until the pH was 4. The resin was filtered and washed with MeOH. The filtrate was evaporated to yield a white solid, 2.49 g (97%); mp 240-243 ⁰C; ¹H NMR (DMSO-d₆) δ 8.98 (s, IH), 8.85 (s, IH), 8.66 (s, IH); ¹³C NMR (DMSO-d₆) δ 161.6, 154.7, 153.3, 144.9, 140.6, 134.2, 128.5; IR(NuJoI) 3134, 3096, 1684, 1642, 1561, 1542, 1509, 1377, 1313, 1257, 1226, 1172, 1123, 1108, 1093, 1061, 982, 954, 919, 851, 754, 732, 666, 616 cm^"1; HRMS (ESI) m/z calculated for C₇H₄N₂O₄Na (M+Na) 203.0069; found 203.0070.

tert-Butyl 2-(2,4'-bioxazoIe-4-carboxamido)-3-hydroxypropanoate (248). A solution of the acid 247 from the previous reaction (2.49 g, 13.8 mmol), EDC (5.3 g, 27.7 mmol) and HOBT (3.74 g, 27.7 mmol) in anhydrous DMF (100 mL) was added to a solution of serine terl- butyl ester (2.23 g, 13.8 mmol) and 2,6-lutidine (16 mL, 138 mmol) in DMF (50 mL) at 0 ⁰C under argon. This stirred and warmed to room temperature overnight. The solvent was removed by Kugelrohr distillation (50 ⁰C, 5 mm Hg) and the resulting residue was partitioned between EtOAc and H₂O. The layers were separated and the organic layer was washed with saturated sodium bicarbonate, 5% HCl, and brine. The organic layer was then dried with Na₂SO₄ and evaporated to a white solid, 3.32 g (74%); mp 85-87 ⁰C; ¹H NMR (CDCl₃) δ 8.30 (d, IH, J=0.73), 8.27 (s, IH), 8.09 (d, IH, J=Ll), 7.85 (d, IH, J=8), 4.73 (dt, IH, J=3.7, 7.7), 4.03 (d, 2H, J=3.7), 1.48 (s, 9H); ¹³C NMR (CDCl₃) δ 168.2, 159.6, 153.7, 151.2, 140.6, 138.6, 136.0, 128.7, 81.9, 62.5, 54.4, 27.1; IR (Thin flim NaCl) 3397, 3143, 2979, 2942, 2252, 1734, 1663, 1597, 1514, 1463, 1397, 1369, 1236, 1158, 1121, 1067, 959, 909, 847, 733 cm^'1; HRMS (ESI) m/z calculated for Ci₄H₁₇N₃O₆Na (M+Na) 346.1015; found 346.1014.

tert-Butyl 2-(2,4'-bisoxazoI-4-yl)-4,5-dihydrooxazoIe-4-carboxylate(249). A solution of the amide 248 (3.32 g. 10.3 mmol) in CH₂Cl₂ (40 mL) was cooled to -78 ⁰C under argon and treated with DAST (2 mL, 15.4 mmol). The reaction was stirred at that same temperature for 4 h and then solid K₂CO₃ (2.13 g, 15.4 mmol) was added. The reaction warmed to room temperature and was then poured into saturated NaHCO₃ solution. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ The combined organic layers were dried over Na₂SO₄ and evaporated to an orange solid, 3.14 g (100%); mp 95-98 ⁰C; ¹U NMR (CDCl₃) δ 8.43 (d, IH, J=0.73), 8.26 (s, IH), 8.04 (d, IH, J=Ll), 4.71 (m, 3H), 1.51 (s, 9H); ¹³C NMR (CDCl₃) δ 168.9, 158.5, 154.7, 151.0, 140.6, 140.4, 138.9, 138.7, 130.4, 128.8, 81.5, 69.2, 68.5, 27.1; IR (thin film NaCl) 3370, 3129, 3063, 2979, 2932, 1733, 1675, 1579, 1539, 1598, 1457, 1369, 1315, 1223, 1157, 1123, 1108, 1063, 988, 957, 908, 890, 845, 753, 715, 667 cm^"1; HRMS (ESI) m/z calculated for C₁₄H₁₅N₃O₅Na (M+Na) 328.0909; found 328.0920.

tert-Butyl teroxazole-4-carboxylate (250). The oxazoline 249 (3.14 g, 10.3 mmol) was dissolved in dry CH₂Cl₂ (30 mL) and placed under argon. After cooling to 0 ⁰C, the solution was treated dropwise with DBU (3.1 mL, 20.6 mmol) and then BrCCl₃ (2.4 mL, 24.7 mmol) over 10 min. The reaction was allowed to warm to room temperature overnight and was then poured into saturated aqueous NH₄Cl. The organic layer was separated and the aqueous solution was extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄ and evaporated under reduced pressure to afford a brown solid. Purification by flash chromatography on SiO₂ eluting with 100% CHCl₃ to 2% MeOH/CHCl₃ gave 1 as a white solid, 1.52 g (49%); mp 283⁰C (dec); ¹H NMR (CDCl₃) δ 8.44 (s, 2H), 8.23 (s, IH), 8.07 (d, IH, J=0.74), 1.61 (s, 9H); ¹³C NMR (CDCl₃) δ 159.1, 155.0, 151.1, 142.3, 138.8, 138.5, 135.0, 130.2, 128.8, 81.6, 27.3; IR (thin film, NaCl) 3178, 3144, 2973, 2360, 2334, 1721, 1647, 1509, 1394, 1363, 1337, 1315, 1295, 1278, 1246, 1151, 1126, 1116, 1099, 1065, 987, 967, 956, 905, 832, 725 cm^"1; HRMS (ESI) m/z calculated for C₁₄H₁₃N₃O₅Na (M+Na) 326.0753; found 326.0750.

tert-Butyl 2"-allylteroxazole-4-carboxylate (251). To a solution of 250 (80 mg, 0.26 mmol) in anhydrous THF (7 mL) at -42 ⁰C under a N₂ atmosphere was slowly added a solution of LiHMDS (528 μL, IM in hexanes) via cannula. CuI (100 mg, 0.53 mmol) was added to the resulting yellow solution after it had stirred for 30 min at -42 ⁰C. After 5 min, allyl bromide (46 μL, 0.53 mmol) was added and the solution was stirred at -42 ⁰C for 30 min. The solution was allowed to slowly warm to room temperature and was stirred overnight. Water (10 mL) was added and the solution was extracted with CH₂Cl₂ (2x20 niL). The organic layer was dried (Na₂SO₄), filtered, and concentrated. The crude product was purified by flash chromatography on SiO₂ eluting with 20% ethyl acetate in hexanes to afford the allylated product as a white solid, 32 mg, (37%); mp 277-279 ⁰C; IR (CHCl₃) 1711 cm^"1; ¹H NMR (CDCl₃) δ 8.37 (s, IH) 8.28 (s, IH), 8.18 (s, IH), 6.00 (m, IH), 5.26 (m, 2H), 3.62 (d, 2H, J= 6.6 Hz), 1.58 (s, 9H); ¹³C NMR (CDCl₃) δ 163.2, 159.1, 155.3, 154.3, 142.2, 138.5, 138.2, 134.9, 130.1, 129.5, 128.9, 118.2, 81.5, 31.6, 27.3; HRMS calcd for C₁₇H₁₇N₃O₅Na (M+Na): 366.1066; found: 366.1065.

2"-AUyIteroxazole-4-carboxylic acid (252). To an ice cold solution of the tert-buty\ ester 251 (55 mg, 0.16 mmol) in CH₂Cl₂ (2 mL) was added anisole (400 μL) followed by TFA (2 mL) and the solution was stirred for 9 h at 0 ⁰C. The reaction mixture was concentrated in vacuo and the solid residue was triturated with diethyl ether (8x5 mL) and the solid was dried under high vacuum to give 252 as a white solid, 41 mg (89%); mp 283-285 ⁰C (dec); IR (CHCl₃) 3135, 1686 cm^"1; ¹H NMR (CDC1₃+CD₃OD) δ 8.38 (s, IH) 8.27 (s, IH), 8.26 (s, IH), 5.91 (m, IH), 5.19 (in, 2H), 3.55 (dt, 2H, J= 1.4, 6.6 Hz); HRMS calcd for C_nH₉N₃O₅H (M+H): 288.0620; found: 288.0622.

2"-|l-(tert-Butoxycarbonyl)amino-2-methyIpropyl]-4-hydroxymethylteroxazole

(253). To a solution of valine teroxazole 213 (100 mg, 0.23 mmol) in THF/EtOH (1 :1, 20 mL) was added LiCl (59 mg, 1.39 mmol) followed by NaBH₄ (53 mg, 1.39 mmol). The solution was stirred at room temperature for 4 h and then water (10 mL) was added. THF and EtOH were removed under reduced pressure and the residue was further diluted with water (20 mL) and then acidified with acetic acid (pH ~6). The aqueous layer was extracted with chloroform (4x20 mL), dried over Na₂SO₄, filtered and the filtrate was evaporated in vacuo. The solid residue was purified by Chromatotron eluting with 2% MeOH in CHCl₃ to afford the title alcohol as a white solid, 68 mg (73%); mp 173-175 ⁰C; IR (CHCl₃) 3430, 3326, 1705 cm^"1; ¹H NMR (CDCl₃) δ 8.31 (s, IH) 8.30 (s, IH), 7.66 (s, IH), 5.36 (d, IH, J= 9.2 Hz), 4.81 (dd, IH, J= 6.2, 9.0 Hz), 4.66 (s, 2H), 2.18 (m, IH), 1.40 (s, 9H), 0.94 (d, 3H, J= 4.0 Hz), 0.90 (d, 3H, J= 3.6 Hz); ¹³C NMR (CDCl₃) δ 164.7, 155.1, 154.4, 154.2, 141.0, 138.4, 137.3, 134.3, 130.6, 128.8, 79.2, 55.9, 53.4, 31.9, 27.3, 17.8, 17.1; HRMS calcd for Ci₉H₂₄N₄O₆Na (M+Na): 427.1594; found: 427.1584.

2"-[l-(tert-Butoxycarbonyl)amino-2-methylpropyI]-4-formylteroxazole (254). To a solution of oxalyl chloride (36 μL, 0.408 mmol) in CH₂Cl₂ (2 mL) at -78 ⁰C under nitrogen was added DMSO (40 μL, 0.571 mmol) and the solution was stirred for -10 min. A solution of the alcohol 253 from the previous reaction (33 mg, 0.081 mmol) in CH₂Cl₂ (5 mL) was added drop wise via cannula and stirred for 10 min at -78 ⁰C. Triethylamine (113 mL, 0.816 mmol) was added and the solution was allowed to warm to room temperature over 20 min with stirring. The reaction mixture was diluted with CH₂Cl₂ (20 mL) and washed with saturated NH₄Cl solution. The organic layer was separated and dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by Chromatotron eluting with 2% MeOH/CHCl₃ to yield aldehyde 254 as a white solid, 29 mg (88%); mp 196-198 ⁰C; IR (CHCl₃) 3373, 1690 cm^"1; ¹H NMR (CDCl₃) δ 10.0 (s, IH), 8.38 (s, IH) 8.33 (s, IH), 8.32 (s, IH), 5.29 (d, IH, J= 9.2 Hz), 4.83 (dd, IH, J= 6.2, 8.8 Hz), 2.23 (m, IH), 1.42 (s, 9H), 0.94 (d, 3H, J= 4.0 Hz), 0.92 (d, 3H, J = 3.0 Hz); ¹³C NMR (CDCl₃) δ 183.1, 164.8, 155.5, 155.0, 154.4, 142.7, 140.7, 138.5, 138.4, 129.8, 128.7, 79.2, 53.4, 32.0, 27.4, 17.8, 17.1; HRMS calcd for C₁₉H₂₂N₄O₆Na (M+Na): 425.1437; found: 425.1432.

2"-[l-(tert-Butoxycarbonyl)amino-2-methyIpropyI]-4-vinylteroxazole (255). A suspension Of CH₃PPh₃Br (88 mg, 0.248 mmol) in anhydrous THF (5 mL) was cooled to 0 ⁰C under nitrogen and rc-BuLi (155 μL, 0.248 mmol, 1.6M in hexanes) was added dropwise via cannula. After stirring at 0 ⁰C for 0.5 h the yellow solution was transferred to a solution of 254 (25 mg, 0.062 mmol) in THF (5 niL) at O ⁰C via cannula and was allowed to warm to room temperature overnight while stirring. The reaction mixture was diluted with water (15 niL) and extracted with CHCl₃. The organic layer was dried over Na₂SO₄, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography eluting with 0.5% MeOH in CH₂Cl₂ to afford the vinyl derivative as a pale yellow solid, 18.3 mg (74%); mp 169- 171 ⁰C; IR (CHCl₃) 3364, 1706 cm^"1; ¹H NMR (CDCl₃) δ 8.32 (s, IH) 8.29 (s, IH), 7.62 (s, IH), 6.58 (dd, IH, J= 11, 17.4 Hz), 6.06 (d, IH₅ J= 17.4 Hz), 5.36 (d, IH, J= 11 Hz), 5.31 (d, IH, J = 10.2 Hz), 4.85 (app t, IH, J= 8.2 Hz), 2.21 (m, IH), 1.44 (s, 9H), 0.96 (d, 3H, J= 2.6 Hz), 0.93 (d, 3H, J= 2.6 Hz); ¹³C NMR (CDCl₃) δ 164.7, 155.1, 154.5, 153.9, 139.6, 138.4, 137.5, 134.1, 130.8, 129.0, 123.8, 116.0, 79.2, 53.5, 32.1, 27.4, 17.8, 17.1; HRMS calcd for C₂₀H₂₄N₄O₅Na (M+Na): 423.1644; found: 423.1631.

2"-(l-Amino-2-methylpropyl)-4-vinylteroxazole (256). The product from the previous reaction (60 mg, 0.15 mmol) was dissolved in CH₂Cl₂ (10 mL) at 0 ⁰C, treated with TFA (2.5 mL), and stirred at 0 °C for 6 h. The reaction mixture was evaporated under reduced pressure and the residue was diluted with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was separated and dried (Na₂SO₄), evaporated, and purified by flash chromatography to afford 256 as a white solid, 33 mg, (73%); mp 125-127 ⁰C; IR (CHCl₃) 3381 cm^"1; ¹U NMR (CDCl₃) δ 8.34 (s, IH) 8.30 (s, IH), 7.63 (s, IH), 6.59 (dd, IH, J= 11, 17.4 Hz), 6.06 (d, IH, J= 17.4 Hz), 5.37 (d, IH, J= 11 Hz), 3.92 (d, IH, J= 6.6 Hz), 2.17 (m, IH), 1.00 (d, 3H, J= 5.6 Hz), 0.96 (d, 3H, J= 7.0 Hz); ¹³C NMR (CDCl₃) δ 167.4, 155.2, 153.9, 139.6, 138.3, 137.4, 134.1, 130.7, 128.7, 123.8, 116.0, 55.0, 32.5, 18.1, 17.1; HRMS calcd for Ci₅H₁₆N₄O₃H (M+H): 301.1301; found: 301.1269.

N-[2"-(2-Methylprop-l-yl)-4-vinylteroxazole]-2"-allylteroxazole-4-carboxamide

(257). To a solution of 256 (10 mg, 0.033 mmol) in DMF (1 mL) at 0 ⁰C under N₂ was added a solution of 252 (9.5 mg, 0.033 mmol), EDC HCl (13 mg, 0.066) and HOBt (9 mg, 0.066 mmol) in DMF (2 mL) and the mixture was stirred for 5 h at room temperature. Water (20 mL) was added and the mixture was extracted with EtOAc (3x25 mL). The organic layers were combined and dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with 2% MeOH in CH₂Cl₂ to afford 257 as a white solid, 13 mg, (69%); mp 235-237 ⁰C (dec); IR (CHCl₃) 3363, 1653 cm^"1; ¹H NMR (CDCl₃) δ 8.34 (s, 2H) 8.33 (s, IH), 8.30 (s, IH), 8.26 (s, IH), 7.62 (s, IH), 7.59 (d, IH, J= 10.4 Hz), 6.57 (dd, IH, J= 11, 17.4 Hz), 6.01 (m, 2H), 5.32 (m, 4H), 3.64 (d, 2H, J= 6.2 Hz), 2.41 (m, IH), 1.07 (d, 3H, J= 7.0 Hz), 1.00 (d, 3H, J= 6.6 Hz); ¹³C NMR (CDCl₃) δ 163.5, 163.3, 159.0, 155.6, 155.0, 153.9, 153.7, 140.7, 139.6, 138.6, 138.5, 138.2, 137.5, 135.9, 134.1, 130.7, 130.0, 129.5, 129.1, 128.8, 123.8, 118.3, 116.0, 51.6, 31.9, 31.6, 18.0, 17.5; HRMS calcd for C₂₈H₂₃N₇O₇H (M+H): 570.1737; found: 570.1732.

Macrocyclic Hexaoxazole (258). A 1.83 mM solution of 257 (13 mg, 0.022 mmol) and the second generation Grubb's catalyst (5.8 mg, 0.007 mmol) in CH₂Cl₂ (12 mL) was heated at reflux for 24 h. The reaction mixture was concentrated in vacuo and purified by Chromatotron eluting with 5% MeOH in CHCl₃ to afford 258 as an off white solid, 3 mg, (32%); mp 195-197 ⁰C (dec); [α]_D= +2° (c 3.7, CHCl₃); IR (CHCl₃) 3149, 1669, 1658 cm^"1; ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.29 (d, IH, J= 8.4 Hz), 8.258 (s, IH) 8.254 (s, IH), 8.23 (s, IH), 8.20 (s, IH), 8.18 (s, IH), 7.60 (m, IH), 7.56 (s, IH), 6.49 (d, IH, J= 15.6 Hz), 5.32 (m, IH), 3.84 (ddd, IH, J= 2.4, 2.8, 19.4 Hz), 3.73 (ddd, IH, J= 8.4, 8.8, 20.2 Hz), 2.39 (m, IH), 1.02 (d, 3H, J= 6.8 Hz), 0.94 (d, 3H, J= 6.8 Hz); ¹³C NMR (CDCl₃) δ 163.4, 163.1, 159.1, 155.7, 154.9, 153.9, 153.8, 140.1, 139.0, 137.6, 137.40, 137.38, 136.29, 136.27, 132.7, 130.8, 130.2, 129.0, 128.9, 127.7, 118.0, 52.2, 33.0, 28.8, 17.7, 17.1; HRMS calcd for C₂₆Hi₉N₇O₇H (M+H): 542.1424; found: 542.1429.

Example 5. Synthesis of compound 259

259

Compound 258 (5.5 mg, 0.01 mmol) and Wilkinson's catalyst (4.6 mg, 0.005 mmol) was taken in a round bottom flask fitted with stirring bar and rubber septa was placed under high vacuum for 0.5 h. Reaction flask was fitted with a hydrogen balloon, ethanol (6 mL) was added and stirred at room temperature for overnight. The reaction mixture was concentrated on rotavap and purified on chromatotron eluting with 8% methanol/chloroform to get a pale yellow solid in 49% yield; [α]_D = (-)2.4° (c 0.125, CHCl₃); IR (neat) 3381, 1655 cm^"1; ¹H NMR (CDCl₃, 400 MHz) δ 8.61 (d, IH, J= 8.4 Hz), 8.20 (s, IH) 8.14 (s, 2H), 8.10 (s, IH), 8.07 (s, IH), 7.42 (s, IH), 5.28 (m, IH), 2.94 (m, IH), 2.85 (m. IH), 2.64 (m, 3H), 2.42 (m, IH), 2.35 (m, IH), 1.04 (d, 3H, J= 6.8 Hz), 0.97 (d, 3H, J= 6.8 Hz); HRMS calcd for C₂₆H₂₁N₇O₇H (M+H): 544.1575; found: 544.1571.

Example 6. Synthesis of Lysine Teroxazole Intermediate 309

A lysine teroxazole intermediate that can be used to prepare compounds of the invention can be prepared as follows a. Synthesis of Compound 301 (NBoc-Cbz Lysine)

N-α-Cbz-(S)-Lysine (5g, 17.85mmol) was dissolved in a mixture of THF (5OmL) and water (5OmL). To this sodium bicarbonate (3g, 35.5mmol, 2eq) and a solution of BoC₂O (9g, 41mmol, 2.3eq) in THF (5OmL). After stirring at room temperature overnight, the THF was removed under reduced pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried with sodium sulfate and concentrated to a clear oil. Removal of excess BoC₂O by Kugelrhor distillation resulted in a thick clear oil weighing 6.8g, 100%. H NMR (CDCl₃) δ 11.6 (s, IH), 7.32 (s, 5H), 6.36 (s, IH), 5.75 (d, IH, J=8), 5.09 (s, 2H), 4.37(m, IH), 3.06 (m, 2H), 1.78 (m, 2H), 1.53 (s, 4H), 1.42 (s, 9H). ¹³C NMR (CDCl₃) δ 174.8, 155.4, 135.4, 127.6, 127.3, 127.2, 78.6, 66.1, 52.9, 39.2, 31.0, 28.6, 27.5, 26.6, 21.4.

b. Synthesis of Compound 302

(DL)-serine methyl ester hydrochloride (2.78g, 17.85mmol leq), BOP (7.9g, 17.85mmol, leq) and 301 (6.8g, 17.85mmol) were dissolved in dry CH₃CN (10OmL). To this triethylamine (6.2mL, 44.6mmol, 2.5eq) was added and the reaction stirred at room temperature overnight. The solvent was then removed in vacuo and the residue was taken up in ethyl acetate. This was washed successively with brine, 2N HCl, 0.5N NaHCO₃, water and brine. The organic layer was dried with sodium sulfate and concentrated to a clear oil weighing 8.6g, 100%. H NMR (CDCl₃) δ 7.50 (m, IH), 7.31 (s, 5H), 6.12 (m, IH), 5.06 (m, 3H), 4.63 (m, IH), 4.30 (m, IH), 3.94 (m, 2H), 3.71 (s, 3H), 3.07 (m, 2H), 1.63 (m, 2H), 1.43 (m, 1IH).¹³C NMR (CDCl₃) δ 171.6, 170.3, 170.0, 155.7, 135.3, 127.6, 127.2, 127.1, 78.3, 66.1, 61.6, 53.8, 51.7, 51.7, 39.0, 31.4, 31.2, 28.5, 27.5, 21.5. IR (thin film, NaCl) 3336, 3068, 3014, 2981, 2937, 2866, 1693, 1525, 1455, 1392, 1366, 1250, 1170, 1061, 912, 849, 755, 698, 666 cm^"1.

c. Synthesis of Compound 303 (Lysine oxazoline)

Compound 302 (8.6g, 17.85mmol) was dissolved in dry CH₂Cl₂ (4OmL) and placed under argon. After cooling to -78⁰C, DAST (3.5mL, 26.8mmol, 1.5eq) was added. After stirring at low temperature for 4 hours, solid K₂CO₃ (3.7g, 26.8mmol, 1.5eq) was added and the reaction warmed to room temperature. The reaction mixture was poured into saturated NaHCO₃ and the layers were separated. The aqueous layer was further extracted with CH₂Cl₂ and the combined organic layers were dried with sodium sulfate. Removal of solvent under reduced pressure afforded the oxazoline as an orange oil weighing 8.3g, 99%. ¹H NMR (CDCl₃) δ 7.34 (s, 5H), 5.67 (t, IH, J=9), 5.10 (s, 2H), 4.73 (m, 2H) 4.46 (m, 3H), 3.77 (s, 3H), 3.00 (m, 2H), 1.75 (m, 2H), 1.42 (s, 13H). ¹³C NMR (CDCl₃) δ 170.4, 170.3, 169.2, 168.8, 155.2, 154.9, 135.4, 127.6, 127.2, 78.1, 69.4, 69.2, 66.9, 66.8, 66.0, 51.8, 48.2, 39.3, 31.9, 31.8, 28.6, 27.5, 21.3, 21.1. IR (thin film, NaCl) 3349, 3069, 3034, 2981, 2953, 2866, 2249, 1705, 1666, 1519, 1455, 1439, 1392, 1366, 1337, 1249, 1174, 1060, 988, 912, 848, 777, 733, 698, 647 cm^"1.

d. Synthesis of Compound 304 (Lysine oxazole) 303

Compound 303 (8.3g, 17.85mmol) was dissolved in dry CH₂Cl₂ (4OmL) and placed under argon. This was cooled to O⁰C and treated dropwise with DBU (5.3mL, 35.7mmol, 2eq) and BrCCl₃ (4.2mL, 42.8mmol, 2.4eq) successively. The reaction mixture turned from orange to dark brown in color and was allowed to warm to room temperature overnight. It was then poured into a solution of saturated ammonium chloride and extracted with CH₂Cl₂. The organic layers were dried with sodium sulfate and concentrated to a brown oil. This was flash chromatographed on SiO₂ with 1-5% methanol/chloroform which gave the product as an amber oil weighing 7.Og, 85%. ¹H NMR (CDCl₃) δ 8.18 (s, IH), 7.31 (m, 6H), 5.71 (d, IH, J=8), 5.10 (s, 2H), 5.00 (m, IH), 4.61 (M, IH), 3.90 (s, 3H), 3.08 (m, 2H), 1.90 (m, 2H), 1.41 (m, 12H). ¹³C NMR (CDCl₃) δ 164.1, 160.5, 155.2, 154.9, 143.1, 135.3, 132.4, 127.6, 127.3, 127.2, 78.3, 76.4, 66.3, 51.3, 48.5, 39.1, 32.7, 28.6, 27.5, 21.5. IR (thin film, NaCl) 3337, 3167, 3069, 3034, 2975, 2952, 2866, 2250, 1705, 1585, 1523, 1455, 1439, 1392, 1366, 1325, 1249, 1170, 1111, 1044, 1002, 912, 863, 805, 733, 698, 647 cm^"1.

e. Synthesis of Compound 305 (Lysine oxazole acid)

Compound 304 (7.Og, 15.23mmol) was dissolved in a 3:1 mixture of THF and water (4OmL) and cooled to O⁰C. To this LiOH (767mg, 18.3mmol, 1.2eq) was added and the reaction warmed to room temperature overnight. After removing the solvent under vacuum, IN HCl (22mL) was added until the pH was slightly acidic. This was extracted with ethyl acetate and the combined organic layers were washed with brine. After drying with sodium sulfate, the organic phase was concentrated to a pale yellow, sticky solid weighing 5.9g, 87%. Melting point 65-67⁰C. ¹H NMR (CDCl₃) δ 12.39 (s, IH), 8.17 (s, IH), 7.25 (m, 6H), 6.52 (m, IH), 5.08 (m, 3H), 4.69 (m, IH), 3.09 (m, 2H), 1.92 (m, 2H), 1.42 (s, 12H). ¹³C NMR (CDCl₃) δ 165.1, 162.7, 155.3, 143.7, 135.3, 132.5, 128.2, 127.6, 127.3, 127.2, 124.4, 78.5, 66.2, 48.5, 39.1, 32.7, 28.5, 27.5, 21.6. IR (thin film, NaCl) 3321, 2934, 2551, 2250, 1701, 1527, 1455, 1367, 1251, 1164, 1111 , 1045, 982, 911, 860, 732, 697, 947 cm^"1. HRMS (FAB) m/z calcd for C₂₂H₂₉N₃O₇Li (M + Li) 455.2194; found, 455.2179.

f. Synthesis of Compound 306 (TIPS bisoxazole)

The TIPS oxazole 315 (synthesis outlined below) (3.58g, 10.47mmol) was dissolved in dry CH₂Cl₂ (2OmL) and placed under argon. To this was added freshly distilled 2, 6-lutidine (6.ImL, 52.4mmol, 5eq) and the flask was cooled to O⁰C. Then a solution of 305 (4.68g, 10.47mmol, leq), EDC (4.02g, 20.94mmol, 1.2eq) and HOBT (2.83g, 20.94mmol, 1.2eq) in CH₂Cl₂ (4OmL) was added. The reaction warmed to room temperature overnight and then the solvent was removed under reduced pressure. The residue was taken up in ethyl acetate and washed successively with saturated NaHCO₃, 5% HCl, water and brine. The organic phase was dried over sodium sulfate and concentrated to an orange oil weighing 7.04g, 87%. ¹H NMR (CDCl₃) δ 8.20 (s, IH), 8.10 (s, IH), 7.39 (d, IH, J=8), 7.35(s, 6H), 5.66 (d, IH, J=8), 5.46 (dt, IH, J = 5, 8), 5.11 (s, 2H), 4.97 (dt, IH J = 7, 7), 4.67 (dd, IH J = 4, 10), 4.20 (m, 3H), 3.79 (s, 3H), 3.90 (m, 2H), 1.90 (m, 2H), 1.42 (m, 1 IH), 1.02 (m, 21H). ¹³C NMR (CDCl₃) δ 163.0, 162.5, 160.6, 159.2, 155.2, 154.9, 143.2, 140.6, 135.3, 134.7, 132.6, 127.6, 127.3, 127.3, 97.4, 78.5, 66.3, 63.9, 51.2, 48.4, 39.2, 32.5, 28.7, 27.5, 21.5, 17.2, 16.9, 12.1, 11.5, 10.9. IR (thin film, NaCl) 3295, 3034, 2944, 2866, 2250, 1712, 1599, 1520, 1461, 1391, 1366, 1324, 1249, 1204, 1171, 1115, 1045, 998, 912, 883, 843, 803, 733, 684, 647 cm^"1. HRMS (FAB) m/z calcd for C₃₈H₅₇N₅O]₀SiLi (M + Li) 778.4029; found 778.4053. g. Synthesis of Compound 307 (Lysine bisoxazole)

Compound 306 (7.2g, 9.3mmol) was dissolved in THF (5OmL) and pyridine (1OmL). This was treated dropwise with HF -pyridine complex (3mL) during which a gas was evolved. The reaction stirred at room temperature for 18 hours and then slowly poured into saturated NaHCO₃. This was extracted with chloroform and dried with sodium sulfate. After concentrating and azeotroping with toluene, the product was obtained as an orange oil weighing 5.76g, 100%. ¹U NMR (CDCl₃) δ 9.09 (d, IH, J=I), 8.26 (s, IH), 8.21 (s, IH), 7.30 (m, 6H), 6.63 (d, IH, J=9), 5.46 (m, IH), 5.08 (s, 2H), 4.68 (m, 2H), 4.26 (m, 2H), 3.86 (s, 3H), 3.07 (m, 2H), 1.43 (s, 12H). ¹³C NMR (CDCl₃) δ 162.9, 162.8, 160.8, 155.2, 143.4, 143.2, 135.4, 134.4, 132.1, 128.2, 127.7, 127.3, 127.2, 124.4, 78.3, 66.2, 63.8, 61.9, 51.5, 51.3, 49.4, 47.5, 39.3, 32.2, 31.2, 28.5, 27.5, 21.7. IR (thin film, NaCl) 3307, 3034, 2945, 2867, 2250, 1712, 1599, 1519, 1456, 1392, 1367, 1324, 1249, 1170, 1113, 1001, 911, 863, 805, 732, 697, 647 cm^"1.

h. Synthesis of Compound 308

Compound 307 (2.76g, 9.3mmol) was dissolved in dry CH₂Cl₂ (4OmL) and placed under argon. After cooling to -78⁰C, DAST (1.8mL, 13.95mmol, 1.5eq) was added and the reaction stirred at low temperature for 4 hours. This was followed by addition of solid K₂CO₃ (1.9g, 13.95mmol, 1.5eq) and the mixture warmed to room temperature. The solution was poured into saturated NaHCO₃ and extracted with CH₂Cl₂. The combined organic layers were dried with sodium sulfate and concentrated to afford an orange oil weighing 5.58g, 100%. ¹H NMR (CDCl₃) δ 8.25 (s, IH), 8.20 (s, IH), 8.11 (d, IH, J=3), 7.91 (d, IH, J = 10), 7.33 (s, 5H), 5.71 (d, IH, J=9 ), 5.53 (m, IH), 5.10 (s, 2H), 4.87 (m, 2H), 4.62 (m, IH), 3.91 (s, 3H), 3.07 (m, 2H), 1.85 (m, 2H), 1.41 (s, 14H). ¹³C NMR (CDCl₃) δ 164.5, 163.0, 162.5, 162.1, 160.4, 159.3, 155.2, 144.0, 143.2, 140.9, 135.3, 134.7, 132.4, 129.1, 127.6, 127.3, 127.2, 78.3, 69.8, 66.2, 63.8, 62.8, 51.3, 48.4, 39.2, 35.5, 32.9, 28.7, 27.5, 21.5, 12.8. IR (thin film, NaCl) 3323, 3155, 3034, 2944, 2867, 2248, 1713, 1584, 1522, 1456, 1391, 1366, 1322, 1249, 1171, 1111, 1044, 995, 914, 885, 804, 775, 733, 698, 646 cm^'1.

1. Synthesis of Compound 309 (Lysine teroxazole)

Compound 308 (5.58g, 9.3mmol) was dissolved in dry CH₂Cl₂ (4OmL) and placed under argon. The flask was cooled to O⁰C and DBU (2.8mL, 18.6mmol, 2eq) and BrCCl₃ (2.2mL, 22.3mmol, 2.4eq) were both added dropwise. This warmed to room temperature overnight and was then poured into saturated ammonium chloride solution. The layers were separated and the aqueous extracted with CH₂Cl₂. The combined organic layers were dried with sodium sulfate and concentrated to a brown oil. Flash chromatography on SiO₂ with 1-2% methanol/chloroform afforded a thick yellow oil. The product obtained from the column was recrystallized from benzene to give white sand like crystals weighing 2.52g, 46%. Melting point 135-137⁰C; Optical rotation [α]_D ²² = -37° (c = lg/lOOmL in CHCl₃). ¹U NMR (CDCl₃) δ 8.44 (s, IH), 8.34 (s, IH), 8.31 (s, IH), 7.35 (m, 5H), 5.68 (d, IH, J=8), 5.12 (s, 2H), 5.04 (m, IH), 4.61 (m, IH), 3.95 (s, 3H), 3.10 (m, 2H), 1.98 (m, 2H), 1.41 (s, 14H). ¹³C NMR (CDCl₃) δ 164.7, 160.4, 155.2, 155.1, 155.0, 154.5, 143.4, 143.0, 139.8, 138.7, 138.5, 135.2, 133.6, 130.0, 128.9, 127.6, 127.4, 127.3, 127.3, 78.3, 66.3, 57.6, 51.4. 48.6, 39.1, 32.7, 28.7, 27.5, 21.5. IR (nujol) 3325, 3156, 3117, 1721, 1689, 1644, 1578, 1518, 1377, 1327, 1247, 1116, 999, 976, 816, 805, 775, 725 cm^"1 HRMS (FAB) m/z calcd for C₂₉H₃₃N₅O₉Li (M+ Li) 602.2433; found 602.2436.

The intermediate Compound 315 used in step f above was prepared as follows. p. Synthesis of Compound 310

Boc-O-benzyl-L-serine (4.13g, 14mmol), serine methyl ester (2.18g, 14mmol) and BOP (6.19 g, 14mmol) were dissolved in CH₃CN (40 niL). Then triethylamine (4.2mL, 30.8mmol, 2.2eq) was added. The reaction stirred overnight at room temperature. The solvent was removed and the residue was dissolved in CH₂Cl₂ and washed successively with brine, 2N HCl, 0.5N NaHCO₃, water and brine. The organic extract was dried over Na₂SO₄ and concentrated to a clear oil weighing 5.54g, 100%. ¹H NMR (CDCl₃) δ 7.31 (s, 6H), 5.49 (d, IH, J = 6), 4.64 (m, IH), 4.55 (s, 2H), 4.31 (m, IH), 3.88 (dd, IH J = 5, 10), 3.75 (s, 3H), 3.63 (dd, IH J = 6, 10), 2.96 (br s, IH), 1.44 (s, 9H). ¹³C NMR (CDCl₃) δ 170.5, 170.3, 155.5, 137.2, 128.3, 127.8, 127.8, 127.7, 80.5, 73.3, 69.8, 69.4, 62.6, 62.4, 60.3, 54.8, 52.5, 28.1. IR (thin film NaCl) 3419, 3065, 3032, 2979, 2954, 2871, 2251, 1670, 1498, 1455, 1439, 1392, 1368, 1248, 1167, 1105, 1027 cm^"1. HRMS (FAB) m/z calcd for Ci₉H₂₈N₂O₇Li (M + Li) 403.2057; found, 403.2052.

q. Synthesis of Compound 311 (serine oxazoline)

Compound 310 (5.54g, 14 mmol) was dissolved in CH₂Cl₂ (2OmL) and placed under argon. After cooling to -78 ⁰C, DAST (2.8mL 21.4mmol, 1.5eq) was added and the reaction stirred at low temperature for 2.5 hours. Then K₂CO₃ 2.9 g, 21.4 mmol, 1.5eq) was added and the reaction warmed to room temperature. This was poured into saturated NaHCO₃. The layers were separated and the aqueous was extracted with CH₂Cl₂. The organic extracts were dried over Na₂SO₄ and concentrated to an orange oil weighing 5.28g, 99%. ¹H NMR (CDCl₃) δ 7.50 (m, 5H), 5.66 (m, IH), 4.99 (dd, IH, J = 8, 10), 4.71 (m, 5H), 3.96 (m, 5H), 1.64 (s, 9H). ¹³C NMR (CDCl₃) δ 170.2, 167.4, 154.3, 136.9, 134.2, 127.5, 126.8, 126.6, 79.0, 72.2, 69.2, 69.0, 67.2, 67.1, 52.5, 51.7, 48.5, 24.7. IR (neat NaCl) 3384, 3063, 3030, 2977, 2870, 1709, 1666, 1506, 1454, 1367, 1322, 1166, 1109, 1051 cm^"1. r. Synthesis of Compound 312 (Boc-O-benzyl serine oxazole)

312

Oxazoline 311 (5.28g, 14mmol) in CH₂Cl₂ (2OmL) was placed under argon and cooled to 0 ⁰C. DBU (3.2 mL, 2mmol, l.όeq) was added dropwise and the solution turned yellow. Then BrCCl₃ (2.2mL, 22.4mmol) was added dropwise and the solution became brown. This warmed to room temperature overnight and then poured into saturated ammonium chloride. The aqueous layer was extracted with CH₂Cl₂. The organic layers were dried over Na₂SO₄ and concentrated to a brown oil. This was flash chromatographed on SiO₂ with 15-50% EtOAc/hexane. The product was obtained as a clear oil 3.1Og, 59%. [α]²⁵ _D -33.35 (c = 2g/100mL in EtOH). ¹H NMR (CDCl₃) δ 8.36 (s, IH) 7.41 (m, 5H), 5.76 (d, IH, J = 8), 5.30 (m, IH), 4.66 (s, 2H), 4.07 (m, 3H), 3.97 (m, 2H), 1.61 (s, 9H). ¹³C NMR (CDCl₃) δ 163.4, 161.3, 154.9, 144.0, 137.2, 133.3, 128.2, 127.7, 127.4, 80.1, 73.1, 70.3, 52.0, 49.2, 28.1. IR (thin film NaCl) 3351, 3163, 3064, 3031, 2978, 2953, 2870, 2251, 1717, 1585, 1499, 1454, 1439, 1392, 13677, 1324, 1251, 1202, 1168, 1112, 1047, 1001 cm^"1.

s. Synthesis of Compound 313 (Boc serine oxazole alcohol)

Compound 312 (3.1Og, 8.24mmol) was dissolved in methanol (5OmL) and 20% palladium hydroxide on carbon (500mg) was added to the reaction vessel. This was hydrogenated in a Parr hydrogenator at 40 psi for 72 hours. The reaction mixture was filtered through Ce lite while washing with methanol. The filtrate concentrated to a clear oil weighing 1.71g, 75% (some material lost in hydrogenator). ¹H NMR (CDCl₃) δ 8.21 (s, IH), 5.67 (s, IH), 5.02 (s, IH), 3.96 (m, 5H), 1.45 (s, 9H). ¹³C NMR (CDCl₃) δ 143.5, 79.7, 62.8, 51.4, 49.8, 27.4 IR (thin film, NaCl) 3364, 2979, 2251, 1716, 1585, 1519, 1456, 1440, 1393, 1368, 1324, 1252, 1168, 1112, 1061, 1001, 915, 861, 804, 774, 733 cm^"1.

t. Synthesis of Compound 314 (Boc-O-TIPS serine oxazole)

314

Compound 313 (1.7Ig, 6mmol) was dissolved in dry DMF (15mL) and imidazole

(1.02g, 15mmol, 2.5eq) was added to the flask. This was placed under argon and treated with TIPS-Cl (1.52mL, 7.2mmol, 1.2eq). The reaction stirred at room temperature overnight and then poured into water. This was extracted with ethyl acetate and the combined organic layers were washed with brine and dried with sodium sulfate. Concentration afforded yellow oil that was flash chromatographed on SiO₂ with 5-15% ethyl acetate/hexane. This was concentrated to a clear oil weighing 1.9g, 72%. ¹H NMR (CDCl₃) δ 8.20 (s, IH), 5.58 (d, IH, J = 8), 5.03 (m, IH), 4.09 (dq, 2H, J = 3, 19), 3.92 (s, 3H), 1.17 (m, 3H), 1.07 (s, 9H), 1.02 (m, 18H). ¹³C NMR (CDCl₃) δ 169.3, 169.1, 163.0, 160.7, 143.1, 132.5, 79.3, 64.1, 51.3, 50.4, 27.4, 17.0, 11.5. IR (thin film NaCl) 3447, 3353, 3159, 3112, 2944, 2892, 2867, 2756, 2723, 2251, 1720, 1585, 1500, 1463, 1391, 1367, 1324, 1250, 1171, 1113, 1068, 998, 920, 882, 804, 766, 733, 684, 660 cm -1

u. Synthesis of Compound 315 (TIPS serine oxazole amine)

Compound 314 (1.9g, 4.3mmol) was dissolved in CH₂Cl₂ (5mL) and cooled to O⁰C.

Then TFA (5 mL) was added and the reaction stirred under a drying tube for 2hours. The reaction mixture was concentrated and azeotroped with benzene twice. The residue was dissolved in CH₂Cl₂ and poured into saturated NaHCO₃. The layers were separated and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried with sodium sulfate and concentrated to a pale yellow oil weighing 1.43g, 97%. ¹H NMR (CDCl₃) δ 8.21 (s. IH), 4.21 (t, IH, J = 5), 4.04 (d, IH, J = 5), 3.92 (s, 3H), 3.74 (d, IH, J = 3), 2.23 (s, 2H), 1.02 (m, 21H). ¹³C NMR (CDCl₃) δ 165.7, 160.8, 143.1, 132.3, 65.5, 55.6, 51.5, 16.9, 10.9. IR (thin film, NaCl) 3376, 3315, 3168, 2944, 2893, 2866, 2762, 2726, 2625, 2247, 1744, 1673, 1583, 1514, 1463, 1439, 1384, 1367, 1345, 1323, 1203, 1110, 1069, 998, 918, 883, 841, 803, 769, 733, 683, 660, 647 cm^"1.

Example 7. Synthesis of EthylamineTeroxazole Intermediate 409

An ethylamine teroxazole intermediate that can be used to prepare compounds of the invention can be prepared as follows.

a. Synthesis of compound 401

BocH N ^/_\ XOOH

NHZ 401 To a suspension of Z-L-2,4-diamino butyric acid (5.0 g, 19.8 mmol) in a mixture of

THF/water (100 mL, 1:1) was added sodium bicarbonate (3.3 g, 39.6 mmol, 2.0 equiv.) and stirred for ] 5 min. Then a solution of BoC₂O (9.9 g, 45.5 mmol, 2.3 equiv.) in THF (50 mL) was added and stirred at room temperature for overnight. Reaction mixture was concentrated and pH was adjusted with 2N HCl to pH ~2. It was extracted with ethyl acetate, dried (Na₂SO₄), filtered and concentrated to clear oil. The oily residue was placed on Kugelrohr to remove excess of

Boc₂O at 85 ⁰C for 2h to get thick clear oil weighing 6.5 g (93%); ¹H NMR (CD₃OD) δ 7.31 (m, 5H), 5.09 (s, 2H), 4.20 (dd, IH, J = 9.2, 4.4), 3.12 (m, 2H), 2.02 (m, IH), 1.78 (m, IH), 1.42 (s, 9H); ¹³C NMR (CD₃OD) δ 174.3, 157.3, 157.1, 136.8, 128.1, 127.6, 127.4, 78.8, 66.3, 51.7, 36.7, 31.6, 27.4.

b. Synthesis of compound 402

A mixture of Z-dab(Boc)-OH (401, 6.3 g, 17.9 mmol), (DL)-serine methyl ester hydrochloride (2.8 g, 17.9 mmol) and BOP (8.7g, 19.7 mmol, 1.1 equiv.) was dissolved in DMF (50 mL) and stirred with diisopropyl ethylamine (6.8 mL, 39.4 mmol, 2.2 equiv.) at room temperature for 8h. Reaction mixture was concentrated on Kugelrohr, diluted with ethyl acetate (250 mL) and washed with 20% aqueous Citric acid (80 mL), saturated sodium bicarbonate solution (100 mL) and brine (100 mL). Organic layer was dried (Na₂SO₄), filtered and concentrated to get a foam like sticky compound weighing 8.0 g (99%); ¹H NMR (CD₃OD) δ 7.34 (m, 5H), 6.54 (m, IH), 5.10 (s, 2H), 4.51 (m, IH), 4.23 (m, IH), 3.88 (m, 2H), 3.72 (s, 3H), 3.17 (m, 2H), 1.98 (m, IH), 1.79 (m, IH), 1.43 (s, 9H); ¹³C NMR (CD₃OD) δ 173.1, 170.7, 157.1, 136.7, 128.1, 127.6, 127.4, 78.8, 66.4, 61.3, 54.8, 52.8, 51.8, 36.6, 32.3, 27.4.

c. Synthesis of compound 403

Compound 402 (8.0 g, 17.6 mmol) was dissolved in anhydrous CH₂Cl₂ (30 mL) and placed under nitrogen. After cooling to -78 ⁰C, DAST (3.47 mL, 26.5 mmol, 1.5 equiv.) was added over a period of 30 min and stirred at the same temperature for 4h. Then solid K₂CO₃ (3.65 g, 26.5 mmol, 1.5 equiv.) was added and stirred for Ih, and the reaction mixture was poured into saturated sodium bicarbonate solution. Aqueous layer was extracted with CH₂Cl₂ (2* 100 mL) and the combined organic layers were dried over Na₂SO₄, filtered and concentrated to get an oily compound weighing 7.60 g (99%); ¹H NMR (CDCl₃) δ 7.21 (m, 5H), 6.16 (m, IH), 5.29 (m, IH), 4.98 (s, 2H), 4.60 (m, IH), 4.35 (m, 3H), 3.62 (s, 3H), 3.16 (m, 2H), 1.91 (m, IH), 1.74 (m, IH), 1.32 (s, 9H); ¹³C NMR (CDCl₃) δ 170.3, 169.0, 155.2, 154.9, 135.3, 127.5, 127.1, 127.0, 77.9, 69.3, 66.7, 65.9, 51.6, 46.3, 35.5, 32.3, 27.4.

d. Synthesis of compound 404

A solution of 403 (7.82 g, 17.9 mmol) in anhydrous CH₂Cl₂ (50 mL) under nitrogen atmosphere was cooled to -5 ⁰C and DBU (5.38 mL, 35.9 mmol, 2.0 equiv.) followed by BrCCl₃ (4.25 mL, 43.1 mmol, 2.4 equiv.) was added over a period of Ih using syringe pump. The reaction mixture was turned from orange to dark brown in color and was allowed to warm to room temperature overnight. Reaction mixture was diluted with saturated sodium bicarbonate solution and CH₂Cl₂ was removed under reduced pressure. Aqueous layer was extracted with ethyl acetate, dried over Na₂SO₄, filtered and concentrated to a brown residue. The residue was purified by flash chromatography eluting with 45% ethyl acetate/hexane get an amber oil weighing 5.44 g (70%); mp 113-115 ⁰C; ¹H NMR (CDCl₃) δ 8.07 (s, IH), 7.19 (s, 5H), 6.36 (d, IH, J = 7.8), 5.18 (m, IH), 4.97 (m, 3H), 3.74 (s, 3H), 3.20 (m, IH), 3.03 (m, IH), 1.99 (m, 2H), 1.29 (s, 9H); ¹³C NMR (CDCl₃) δ 163.8, 160.4, 155.3, 155.1, 143.3, 135.2, 132.1, 127.5, 127.1, 127.0, 78.2, 66.1, 51.1, 46.3, 35.7, 32.9, 27.4.

e. Synthesis of compound 405

Compound 404 (5.4 g, 12.5 mmol) was dissolved in a 3:1 mixture of THF/water (40 mL) and cooled to 0 ⁰C. To this LiOH (628 mg, 14.9 mmol, 1.2 equiv.) was added and stirred at room temperature for 3h. Reaction mixture was concentrated to remove THF and diluted with ether. Ether layer was decanted, and the aqueous layer was acidified with 2N HCl (~pH 2) and extracted with ethyl acetate. Organic layer was washed with water, dried over Na₂SO₄, filtered and concentrated to get a white solid weighing 4.96 g (95%); mp 52-53 ⁰C; ¹H NMR (CDCl₃) δ 9.01 (s, IH), 8.13 (s, IH), 7.26 (s, 5H), 6.48 (d, IH, J = 8.4), 5.05 (m, 4H), 3.13 (m, 2H), 2.12 (m, 2H), 1.38 (s, 9H); ¹³C NMR (CDCl₃) δ 164.3, 162.4, 155.4, 143.9, 135.1, 132.3, 127.5, 127.2, 127.1, 78.8, 66.3, 46.4, 35.7, 33.2, 27.4.

f. Synthesis of 406

406 Compound 204 (5.5 g, 19.9 mmol) was dissolved in EtOH/THF (3 : 1 , 300 mL) and added

TFA (6.14 mL, 79.7 mmol, 4.0 equiv.) followed by Pd(OH)₂ (2.0 g) and stirred at room temperature under hydrogen atmosphere for 24 h. Reaction mixture was filtered through celite and the filtrate was concentrated under vacuum. The residue was further dried under high vacuum to get sticky brown solid weighing 3.6 g (97%); ¹H NMR (CD₃OD) δ 8.65 (s, IH), 4.73 (t, IH, J = 4.8), 4.07 (d, 2H, J = 4.6), 3.89 (s, 3H); ¹³C NMR (CD₃OD) δ 161.6, 159.3, 146.1, 133.0, 60.0, 51.6, 50.5.

g. Synthesis of compound 407

BocHN

To a solution of 406 (2.2 g, 11.8 mmol) and 2,6-lutidine (6.85 mL, 59.0 mmol, 5.0 equiv.) in DMF (25 mL) at 0 ⁰C under nitrogen atmosphere, a solution of 405 (4.95 g, 11.8 mmol), HOBT (3.21 g, 23.6 mmol, 2.0 equiv.), EDC (4.53 g, 23.6 mmol, 2.0 equiv.) in DMF (45 mL) was added and stirred at room temperature for 16h. Reaction mixture was concentrated on Kugelrohr, diluted with 20% citric acid (100 mL) and extracted with ethyl acetate (200 mL). Organic layer was washed with saturated sodium bicarbonate solution (3*100 mL), brine (100 mL), dried over Na₂SO₄, filtered and concentrated to get a brown solid weighing 6.83 g (98%); ¹H NMR (CD₃OD) δ 8.53 (s, IH), 8.34 (s, IH), 7.32 (s, 5H), 6.60 (m, IH), 5.36 (t, IH, J = 5.3), 5.10 (s, 2H), 4.90 (m, IH), 4.05 (d, 2H, J = 5.6), 3.86 (s, 3H), 3.16 (m, 2H), 2.12 (m, 2H), 1.41 (s, 9H); ¹³C NMR (CD₃OD) δ 164.3, 163.2, 161.6, 161.2, 156.9, 145.1, 142.3, 136.6, 135.4, 132.8, 128.2, 127.8, 127.6, 78.8, 66.6, 61.9, 60.2, 51.4, 49.6, 36.7, 32.8, 27.6.

g. Synthesis of compound 408

Compound 407 (6.83 g, 11.6 mmol) was dissolved in anhydrous CH₂Cl₂ (60 mL) and placed under nitrogen. After cooling to -78 ⁰C, DAST (2.28 ml, 17.4 mmol, 1.5 equiv.) was added over a period of 30 min and stirred at the same temperature for 4h. Then solid K₂CO₃ (2.40 g, 17.4 mol, 1.5 equiv.) was added and stirred for Ih, and the reaction mixture was poured into saturated sodium bicarbonate solution. Aqueous layer was extracted with CH₂Cl₂ and the combined organic layers were dried over Na₂SO₄, filtered and concentrated to get an oily compound weighing 6.1 g (92%); ¹H NMR (CDCl₃) δ 8.15 (s, IH), 8.02 (s, IH), 7.26 (s, 5H), 5.69 (m, IH), 5.47 (m, IH), 4.99 (m, 4H), 4.72 (m, 2H), 3.84 (s, 3H), 3.24 (m, IH), 3.04 (m, IH), 2.12 (m, IH), 1.88 (m, IH), 1.34 (s, 9H).

h. Synthesis of compound 409

A solution of 408 (6.1 g, 10.7 mmol) in anhydrous CH₂Cl₂ (50 mL) under nitrogen atmosphere was cooled to -5 ⁰C and DBU (3.2 mL, 21.4 mmol, 2.0 equiv.) followed by BrCCl₃ (2.5 mL, 25.7 mmol, 2.4 equiv.) was added over a period of 0.5h using syringe pump. The reaction mixture was turned from orange to dark brown in color and started precipitating out. To this, anhydrous CH₂Cl₂ (100 mL) was added and allowed to warm to room temperature overnight. Reaction mixture was diluted with saturated sodium bicarbonate solution and CH₂Cl₂ was removed under reduced pressure. Aqueous layer was extracted with chloroform, dried over Na₂SO₄, filtered and concentrated to a brown residue.

Example 8. The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.

(ϊ) Tablet 1 mg/tablet

Compound X= 100.0

Lactose 77.5

Povidone 15.0

Croscarmellose sodium 12.0

Microcrystalline cellulose 92.5

Magnesium stearate 3.0

300.0 (ii) Tablet 2 mg/tablet

Compound X= 20.0

Macrocrystalline cellulose 410.0

Starch 50.0

Sodium starch glycolate 15.0

Magnesium stearate 5.0

500.0

(iii) Capsule me/capsule

Compound X= 10.0

Colloidal silicon dioxide 1.5

Lactose 465.5

Pregelatinized starch 120.0

Magnesium stearate 3.0

600.0

(iv) Injection 1 (1 me/ml) mg/ml

Compound X= (free acid form) 1.0

Dibasic sodium phosphate 12.0

Monobasic sodium phosphate 0.7

Sodium chloride 4.5

1.0 N Sodium hydroxide solution

(pH adjustment to 7.0-7.5) q.s.

Water for injection q.s. ad 1 niL

(v) Injection 2 (10 mg/ml) mg/ml

Compound X= (free acid form) 10.0

Monobasic sodium phosphate 0.3

Dibasic sodium phosphate 1.1

Polyethylene glycol 400 200.0

01 N Sodium hydroxide solution

(pH adjustment to 7.0-7.5) q.s.

Water for injection q.s. ad 1 mL

(vi) Aerosol mg/can

Compound X= 20.0

Oleic acid 10.0

Trichlorom onofluoromethane 5,000.0

Dichlorodi fluoromethane 10,000.0

Dichlorotetrafluoroethane 5,000.0

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.

AU publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

What is claimed is:

1. A compound of formula (I):

(I) wherein: one of A and B is -CH(R^b)CH(R^c)C(R^d)(R^e)-; and the other of A and B is:

; -CH(R^a)NHC(=O)- or -CH(R^b')CH(R^c')C(R^d')(R^e')-; one of F and G is X and the other is C(R^); each X is independently NH, S, or O; the dotted line in the ring containing F and G signifies that two double bonds are present in the ring, the positions of which depend upon the values selected for F and G; n and n' each independently represents 1, 2, 3, 4 and 5, provided that the sum of n and n' is 6;

R ^a represents hydrogen, (C]-C₆)alkyl, (C₂-C₆)alkenyl, (Ci-C₆)alkoxy or (C₁ - C₆)alkanoyloxy, wherein each (Ci-C₆)alkyl, (C₂-C₆)alkenyl, (Ci-C₆)alkoxy and (C₁- C6)alkanoy]oxy is optionally substituted with OH, (CrC₆)alkoxy, (Ci-C₆)alkylthio, aryl, heteroaryl, NR^Rg, or -C(=O)NRfRg; and wherein each aryl and heteroaryl is optionally substituted with one or two substituents selected independently from halo, hydroxy, (Ci-

C₆)alkyl, NRfRg, and NR^fRg(C₁-C₆)alkyl-

R^ and R^c each represents hydrogen, or R^b and R^c together represent a bond or -O-; Rd and R^e together represent (=0) or Rd represents hydrogen and R^e represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=0)0R^s or CH₂C(=O)NR^mRⁿ, wherein each (CrC₆)alkanoyloxy is optionally substituted with one or more NR*R^U;

R^' and R^c' each represents hydrogen, or R^' and R^c'together represent a bond or -O-; R^' and R^e' together represent (=0) or Rd' represents hydrogen and R^e' represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=O)OR^S or CH₂C(=0)NR^mRⁿ, wherein each (Ci-C₆)alkanoyloxy is optionally substituted with one or more NR*R^U; each of Rf and RS is independently hydrogen, (Ci-C₆)alkyl or (C₁-C₆)alkanoyl, which

(Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or Rf and RS together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RJ and R^k is independently hydrogen or (Cj-C₆)alkyl, which (C]-C₆)alkyl is optionally substituted with one or more NR¹R¹¹; or RJ and R^k together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of R^m and Rⁿ is independently hydrogen or (CrC₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR^R^U; or R^m and Rⁿ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of Rl, R^, and R^ is independently hydrogen (Ci-C₆)alkyl, (C₁-C₆)alkoxy, aryl or heteroaryl wherein each (Ci-C₆)alkyl and (C]-C₆)alkoxy is optionally substituted with OH, (C₁-

C₆)alkoxy, (d-C₆)alkylthio, aryl, NR⁰RP, or -C(=O)NRqR^r; and wherein each aryl or heteroaryl is optionally substituted with one or two substituents selected independently from a halogen atom and (C₁-C₄)alkyl wherein (C_rC₄)alkyl is optionally substituted with NR⁰RP; each of R⁰ and RP is independently hydrogen or (Ci-C₆)alkyl, which (CrC₆)alkyl is optionally substituted with one or more NR*R^U; or R⁰ and RP together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; and each of RQ and R^r is independently hydrogen or (Ci-C₆)alkyl, which (C]-C₆)alkyl is optionally substituted with one or more NR¹R¹¹; or RQ and R^r together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring;

R^s is hydrogen or (C₁-C₆)alkyl, which (d-C₆)alkyl is optionally substituted with one or more NR^1tR^u; each of Rt and R^u is independently hydrogen, (d-C₆)alky or (Ci-C₆)alkanoyl; or R¹ and R^u together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; or a salt thereof.

2. The compound of claim 1 wherein: one of A and B is -CH(R^b)CH(R^c)C(R^d)(R^e)-; and the other of A and B is:

or -CH(Rb')CH(R^c')C(Rd')(Re')-_; one of F and G is X and the other is C(R^); each X is independently NH, S, or O; the dotted line in the ring containing F and G signifies that two double bonds are present in the ring, the positions of which depend upon the values selected for F and G; n and n' each independently represents 1, 2, 3, 4 and 5, provided that the sum of n and n' is 6;

R^a represents hydrogen, (C₁-C₆)alkyl, (C_!-C₆)alkoxy or (Ci-C₆)alkanoyloxy, wherein each (Ci-C₆)alkyl, (C_rC₆)alkoxy and (C]-C₆)alkanoyloxy, is optionally substituted with OH,

(Ci-C₆)alkoxy, (C_rC₆)alkylthio, aryl, heteroaryl, NR^tS or -C(=O)NR*Rg; and wherein each aryl and heteroaryl is optionally substituted with one or two substituents selected independently from halo, (Ci-C₆)alkyl, NR^Rg and NR^fRg(Ci-C₆)alkyl-

R^b and R^c each represents hydrogen, or R^b and R^c together represent a bond or -O-; R^ and R^e together represent (=0) or Rd represents hydrogen and R^e represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=O)OR^S or CH₂C(=0)NR^mRⁿ, wherein each (Ci-C₆)alkanoyloxy is optionally substituted with one or more NR*R^U;

R^' and R^c' each represents hydrogen, or R^' and R^c'together represent a bond or -O-; Rd' and R^e' together represent (=0) or R^' represents hydrogen and R^e' represents hydrogen, hydroxy, (Ci-C₆)alkanoyloxy, NRJR^k, CH₂C(=0)0R^s or CH₂C(=O)NR^mRⁿ, wherein each (C]-C₆)alkanoyloxy is optionally substituted with one or more NR^lR^u; each of Rf and RS is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR^lR^u; or Rf and RS together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RJ and R^ is independently hydrogen or (Ci-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR*R^U; or RJ and R^ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of R^m and Rⁿ is independently hydrogen or (Ci-C₆)alkyl, which (CrC₆)alkyl is optionally substituted with one or more NR¹R¹¹; or R^m and Rⁿ together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; each of RI , R^, and R^ is independently hydrogen, (Ci-C₆)alkyl, (Ci-C₆)alkoxy , aryl or heteroaryl wherein each (Cj-C₆)alkyl and (Ci-C₆)alkoxy is optionally substituted with OH,

(Ci-C₆)alkoxy, (Ci-C₆)alkylthio, aryl, NR⁰RP, or -C(=O)NRqR^r; and wherein each aryl or heteroaryl is optionally substituted with one or two substituents selected independently from a halogen atom and (Ci-C₄)alkyl wherein (Q-C^alkyl is optionally substituted with NR⁰RP; each of R⁰ and RP is independently hydrogen or (CrC₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NRtR^u; or R⁰ and RP together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring; and each of RI and R^r is independently hydrogen or (Ci-C₆)alkyl, which (CrC₆)alkyl is optionally substituted with one or more NR*R^U; or RQ and R^r together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring;

R^s is hydrogen or (C]-C₆)alkyl, which (Ci-C₆)alkyl is optionally substituted with one or more NR¹R¹¹; each of R* and R^u is independently hydrogen, (C]-C₆)alkyl or (Ci-C₆)alkanoyl, or Rt and R^u together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or azepino ring.

3. A compound as claimed in claim 1 or claim 2, in which n and n' each represents 3.

4. A compound as claimed in any one of claims 1- 3, which is selected from formulae:

(Ia')

(Ia")

(Ib')

(Ib")

10

(Ic')

(Id')

10

10 (If").

5. A compound as claimed in any one of claims 1- 3, which is selected from formulae (Ia'):

(Ia').

A compound as claimed in any one of claims 1-3, which is selected from formulae (Ig'):

(Ig')-

7. A compound as claimed in any one of claims 1- 3, which is selected from formulae (Ih'):

(Ih')-

8. A compound as claimed in any one of claims 1-7, in which each X is O.

9. A compound as claimed in any one of claims 1 -8, in which each Rl is hydrogen.

10. A compound as claimed in any one of claims 1-9, in which each R^ is hydrogen.

11. A compound as claimed in any one of claims 1-5, in which R^a is selected from hydrogen, methyl, isopropyl, 1-methylpropyl, 2-methylpropyl, benzyl, 4-hydroxybenzyl, 4-iodobenzyl, 4-aminobenzyl, and 4-(2-N,N- dimethylaminoethylamino)benzyl ;

R^ and R^c are, together are a bond; R^d is hydrogen and R^e is hydrogen, hydroxy, CH₂C(=O)OCH3, CH₂C(=O)N(CH₃)₂, or

CH₂C(=O)NHCH₂CH₂N(CH₃)₂.

12. A compound as claimed in any one of claims 1-5 and claim 11, in which

R^b and R^c' together are a bond; R^d' is hydrogen; and

R^e' is hydrogen, hydroxy, CH₂C(=O)OCH₃ or CH₂C(=O)N(CH₃)₂, or CH₂C(=O)NHCH₂CH₂N(CH₃)₂.

13. A compound as claimed in any one of claims 1-10, in which R^a is alkyl.

14. A compound as claimed in any one of claims 1-10, in which R^a is isopropyl.

15. A compound as claimed in any one of claims 1-10 in which R^a is (d-C₆)alkyl or (C₂- C₆)alkenyl wherein each (CrC₆)alkyl, and (C₂-C₆)alkenyl, is optionally substituted with NRfRg.

16. A compound as claimed in any one of claims 1-10 in which R^a is aminomethyl, 2- aminoethyl, 3-aminopropyl or 4-aminobutyl.

17. A compound as claimed in any one of claims 1-16, in which R^d and R^e are hydrogen.

18. The compound of claim 1 which is

or a salt thereof.

19. The compound of claim 1 which is,

or a salt thereof.

20. The compound of claim 1 which is,

or a salt thereof.

21. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1-20; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

22. A therapeutic method for treating cancer comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula (I) as defined in any one of claims 1-20, or a pharmaceutically acceptable salt thereof.

23. A method to stabilize G-quadruplex DNA comprising contacting the G-quadruplex DNA with a compound of formula I as defined in any one of claims 1-20, or a salt thereof.

24. A compound as defined in any one of claims 1-20, or a pharmaceutically acceptable salt thereof for use in medical therapy.

25. The use of a compound as defined in any one of claims 1-20, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment of cancer in a mammal.

26. A compound as defined in any one of claims 1-20 or a pharmaceutically acceptable salt thereof for use in the prophylactic or therapeutic treatment of cancer.

27. The use of claim 25 wherein the cancer is nasopharynx cancer, breast cancer, pancreatic cancer, leukemia, acute leukemia, ovarian cancer, colon cancer, head cancer and neck cancer.

28. The compound of claim 26 wherein the cancer is nasopharynx cancer, breast cancer, pancreatic cancer, leukemia, acute leukemia, ovarian cancer, colon cancer, head cancer and neck cancer.